

Financial news for HZNP dated on 2020-06-03: UPDATE: Horizon Therapeutics' KRYSTEXXA MIRROR Open-Label Trial Shows 79% Of Patients Achieved Complete Response

Financial news for HZNP dated on 2020-06-03: Data Presented on KRYSTEXXA(r) (pegloticase injection) Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach

Financial news for HZNP dated on 2020-05-29: Stocks That Hit 52-Week Highs On Friday

Financial news for HZNP dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for HZNP dated on 2020-05-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for HZNP dated on 2020-05-26: B of A Securities Reiterates Buy on Horizon Therapeutics, Raises Price Target to \$57

Financial news for HZNP dated on 2020-05-22: Stocks That Hit 52-Week Highs On Friday

Financial news for HZNP dated on 2020-05-22: The Daily Biotech Pulse: FDA Nod For Aquestive, Tetrphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

Financial news for HZNP dated on 2020-05-21: Stocks That Hit 52-Week Highs On Thursday

Financial news for HZNP dated on 2020-05-21: Horizon Therapeutics To Present Data On KRYSTEXXA At European Congress Of Rheumatology

Financial news for HZNP dated on 2020-05-19: In The Midst Of Pandemic, Traders Pin Their Hopes On These Healthcare ETFs

Financial news for HZNP dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for HZNP dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for HZNP dated on 2020-05-14: Horizon Therapeutics To Present New Data On Pharmacokinetic Profile Of TEPEZZA

Financial news for HZNP dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for HZNP dated on 2020-05-12: Horizon Pharma Shares Volatile On Volume Spike; Hearing CEO To Appear On CNBC Shortly

Financial news for HZNP dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for HZNP dated on 2020-05-11: Stocks That Hit 52-Week Highs On Monday

Financial news for HZNP dated on 2020-05-08: Morgan Stanley Maintains Overweight on Horizon Therapeutics, Raises Price Target to \$50

Financial news for HZNP dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for HZNP dated on 2020-05-07: 66 Biggest Movers From Yesterday

Financial news for HZNP dated on 2020-05-06: 58 Stocks Moving In Wednesday's Mid-Day Session

Financial news for HZNP dated on 2020-05-06: Stocks That Hit 52-Week Highs On Wednesday

Financial news for HZNP dated on 2020-05-06: Horizon Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for HZNP dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for HZNP dated on 2020-05-06: 19 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for HZNP dated on 2020-05-06: Horizon Therapeutics Raises FY20 Sales Guidance From \$1.40B-\$1.42B To \$1.40B-\$1.45B vs \$1.35B Est.

Financial news for HZNP dated on 2020-05-06: Horizon Therapeutics Q1 Adj. EPS \$0.400 Beats \$0.210 Estimate, Sales \$355.900M Beat \$287.880M Estimate

Financial news for HZNP dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for HZNP dated on 2020-04-28: Jefferies Maintains Buy on Horizon Therapeutics, Raises Price Target to \$51

Financial news for HZNP dated on 2020-04-27: Horizon Therapeutics Announces Availability Of PROCYSBI Delayed-Release Oral Granules In Packets In The United States

Financial news for HZNP dated on 2020-04-14: Piper Sandler Maintains Overweight on Horizon Therapeutics, Lowers Price Target to \$44

Financial news for HZNP dated on 2020-04-02: Morgan Stanley Maintains Overweight on Horizon Therapeutics, Lowers Price Target to \$39

Financial news for HZNP dated on 2020-04-02: Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. And Its LPAR1 Antagonist Product Candidate For \$45M Upfront In Cash And Additional Payments Contingent Upon Milestones

Financial news for HZNP dated on 2020-03-31: Horizon Therapeutics Shares Quiet Following Co. Press Release Highlighting Co.'s TEPEZZA 'Significantly' Reduces Proptosis Across Patient Subtypes

Financial news for HZNP dated on 2020-03-23: B of A Securities Maintains Buy on Horizon Therapeutics, Lowers Price Target to \$42

Financial news for HZNP dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for HZNP dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for HZNP dated on 2020-02-26: Horizon Therapeutics PLC shares are trading higher after the company reported better-than-expected Q4 EPS and sales results. The company also issued FY20 sales guidance above analyst estimates.

Financial news for HZNP dated on 2020-02-26: Horizon Therapeutics Sees FY20 Sales \$1.40B-\$1.42B vs \$1.39B Est.

Financial news for HZNP dated on 2020-02-26: Horizon Therapeutics Q4 EPS \$0.56 Beats \$0.43 Estimate, Sales \$363.545M Beat \$349.24M Estimate

Financial news for HZNP dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for HZNP dated on 2020-02-18: Horizon Therapeutics Reports FDA Approval Of New Dosage Form For PROCYSBI Delayed-Release Oral Granules

Financial news for HZNP dated on 2020-02-18: Horizon Therapeutics plc Announces FDA Approval Of New Dosage Form For PROCYSBI Delayed-Release Oral Granules

Financial news for HZNP dated on 2020-01-28: Horizon Therapeutics Announces It Will Purchase Three-Building Campus In Deerfield; Terms Not Disclosed.

Financial news for HZNP dated on 2020-01-26: The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes

Financial news for HZNP dated on 2020-01-23: The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment

Financial news for HZNP dated on 2020-01-22: BMO Capital Maintains Outperform on Horizon Therapeutics, Raises Price Target to \$46

Financial news for HZNP dated on 2020-01-22: Stocks That Hit 52-Week Highs On Wednesday

Financial news for HZNP dated on 2020-01-22: The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

Financial news for HZNP dated on 2020-01-21: Hearing FDA Approves Horizon Therapeutics Thyroid Eye Disease Treatment

Financial news for HZNP dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for HZNP dated on 2020-01-14: The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

Financial news for HZNP dated on 2020-01-13: Horizon Therapeutics Announces 79% Of Patients Achieved A Complete Response In MIRROR Open-Label Pilot Study, Supporting KRYSTEXXA Immunomodulation Strategy To Optimize Treatment Outcomes

Financial news for HZNP dated on 2020-01-13: Horizon Therapeutics Raises Prelim. FY19 KRYSTEXXA Sales Guidance From \$750M To \$1B+

Financial news for HZNP dated on 2020-01-08: Goldman Sachs Initiates Coverage On Horizon Therapeutics with Neutral Rating, Announces \$35 Price Target

Financial news for HZNP dated on 2019-12-27: The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

Financial news for HZNP dated on 2019-12-26: The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

Financial news for HZNP dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for HZNP dated on 2019-12-20: Stocks That Hit 52-Week Highs On Friday

Financial news for HZNP dated on 2019-12-20: The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

Financial news for HZNP dated on 2019-12-19: Stocks That Hit 52-Week Highs On Thursday

Financial news for HZNP dated on 2019-12-19: The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Financial news for HZNP dated on 2019-12-18: The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

Financial news for HZNP dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for HZNP dated on 2019-12-16: UPDATE: Morgan Stanley On Horizon Therapeutics Thinks 'that the set up for HZNP remains encouraging entering 2020 given upward pressure on teprotumumab and Krystexxa sales and improving business mix'

Financial news for HZNP dated on 2019-12-16: UPDATE: Morgan Stanley Reiterates Overweight On Horizon Therapeutics, Raises Target To \$38 'Following the Dec. 13 unanimous FDA panel meeting in favor of tepro approval'

Financial news for HZNP dated on 2019-12-16: Stifel Nicolaus Maintains Buy on Horizon Therapeutics, Raises Price Target to \$40

Financial news for HZNP dated on 2019-12-16: BMO Capital Maintains Outperform on Horizon Therapeutics, Raises Price Target to \$40

Financial news for HZNP dated on 2019-12-16: Morgan Stanley Maintains Overweight on Horizon Therapeutics, Raises Price Target to \$38

Financial news for HZNP dated on 2019-12-16: Stifel Maintains Buy on Horizon Therapeutics, Raises Price Target to \$40

Financial news for HZNP dated on 2019-12-16: A Peek Into The Markets: US Stock Futures Up Ahead Of Economic Data

Financial news for HZNP dated on 2019-12-16: 5 Stocks To Watch For December 16, 2019

Financial news for HZNP dated on 2019-12-13: Horizon Therapeutics Says FDA Advisory Committee Has Voted Unanimously To Support Use Of Teprotumumab For Thyroid Eye Disease

Financial news for HZNP dated on 2019-12-13: Horizon Shares Halted Ahead Of FDA Dermatologic and Ophthalmic Drugs Advisory Committee Meeting To Discuss Teprotumumab For Thyroid Eye Disease; Meeting Runs From 8 a.m. To 4 p.m. EST

Financial news for HZNP dated on 2019-12-13: Horizon Pharma Shares Halted News Pending

Financial news for HZNP dated on 2019-11-27: The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

Financial news for HZNP dated on 2019-11-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for HZNP dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for HZNP dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for HZNP dated on 2019-11-22: Stocks That Hit 52-Week Highs On Friday

Financial news for HZNP dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Collectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for HZNP dated on 2019-11-20: Stocks That Hit 52-Week Highs On Wednesday

Financial news for HZNP dated on 2019-11-06: Stocks That Hit 52-Week Highs On Wednesday

Financial news for HZNP dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for HZNP dated on 2019-11-06: Horizon Therapeutics Reaffirms FY19 Sales Guidance \$1.28B-\$1.3B vs \$1.28B Estimate, Raises Adj. EBITDA Guidance To \$465M-\$475M

Financial news for HZNP dated on 2019-11-06: Horizon Therapeutics Q3 EPS \$0.64 Beats \$0.49 Estimate, Sales \$335.466M Beat \$329.76M Estimate

Financial news for HZNP dated on 2019-11-05: Stocks That Hit 52-Week Highs On Tuesday

Financial news for HZNP dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for HZNP dated on 2019-11-04: Stocks That Hit 52-Week Highs On Monday

Financial news for HZNP dated on 2019-11-04: Horizon Therapeutics to Present an Integrated Analysis of Efficacy Data From Phase 2 and 3 Trials of Teprotumumab During the American College of Rheumatology Annual Meeting

Financial news for HZNP dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for HZNP dated on 2019-10-31: Horizon Therapeutics Reports Data From Phase 2, Phase 3 Trial Of Teprotumumab For Treatment Of Active Thyroid Eye Disease vs Placebo

Financial news for HZNP dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for HZNP dated on 2019-10-29: Stocks That Hit 52-Week Highs On Tuesday

Financial news for HZNP dated on 2019-10-24: Horizon Therapeutics To Present New Combined Data From Phase 2 And Phase 3 Teprotumumab Clinical Trials At American Thyroid Association Annual Meeting

Financial news for HZNP dated on 2019-10-17: Horizon Therapeutics Initiates PROTECT Trial Evaluating KRYSTEXXA To Improve Management Of Uncontrolled Gout For Adults With Kidney Transplant

Financial news for HZNP dated on 2019-10-16: 4 Stocks Nearing Key Breakouts

Financial news for HZNP dated on 2019-09-26: UPDATE: Bank Of America Initiates Horizon Therapeutics With Buy, \$34 Target As Firm's Thesis Is Driven By 'tepro approval and favorable payer coverage for TED', 'Krystexxa (gout) continued execution of re-launch and read-across to tepro launch hurdles'

Financial news for HZNP dated on 2019-09-26: Benzinga's Top Upgrades, Downgrades For September 26, 2019

Financial news for HZNP dated on 2019-09-26: Bank of America Initiates Coverage On Horizon Therapeutics with Buy Rating, Announces \$34 Price Target

Financial news for HZNP dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug

price reform proposal would be dead on arrival.

Financial news for HZNP dated on 2019-09-12: UPDATE: Guggenheim On Horizon Also Notes Potential Catalysts: 'Teprotumumab PDUFA / launch (1Q20), SELB data vs. KKK (4Q19-1Q20), KKK kidney transplant and methotrexate data (2021)'

Financial news for HZNP dated on 2019-09-12: UPDATE: Guggenheim Initiates Horizon With Buy, \$36 Target As Firm Believes Co. Is 'EV-103 data at ESMO could hint at larger opportunity in bladder cancer'; Sees 'upside to estimates on Krystexxa /Teprotumumab top line growth (we are modestly above cons.)'

Financial news for HZNP dated on 2019-09-12: Benzinga's Top Upgrades, Downgrades For September 12, 2019

Financial news for HZNP dated on 2019-09-12: Guggenheim Initiates Coverage On Horizon Therapeutics with Buy Rating, Announces \$36 Price Target

Financial news for HZNP dated on 2019-09-09: Horizon Therapeutics Announces FDA Has Granted Priority Review To Teprotumumab Biologics License Application For The Treatment Of Active Thyroid Eye Disease

Financial news for HZNP dated on 2019-08-14: Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade

Financial news for HZNP dated on 2019-08-14: Benzinga's Top Upgrades, Downgrades For August 14, 2019

Financial news for HZNP dated on 2019-08-14: 10 Biggest Price Target Changes For Wednesday

Financial news for HZNP dated on 2019-08-14: BMO Capital Upgrades Horizon Therapeutics to Outperform, Raises Price Target to \$36

Financial news for HZNP dated on 2019-08-07: Horizon Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also raised FY19 sales guidance above analyst estimates.

Financial news for HZNP dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for HZNP dated on 2019-08-07: Horizon Therapeutics Raises FY19 Sales Guidance From \$1.26B-\$1.28B To \$1.28B-\$1.30B vs \$1.26B Est.

Financial news for HZNP dated on 2019-08-07: Horizon Therapeutics Q2 Adj. EPS \$0.49 Beats \$0.37 Estimate, Sales \$320.6M Beat \$297.07M Estimate

Financial news for HZNP dated on 2019-08-01: Horizon Therapeutics Reports Teprotumumab Expanded Access Program

Financial news for HZNP dated on 2019-07-30: Horizon Therapeutics Announces Court Of Appeals Denied Company's Request For A Rehearing Of Court's Invalidity Ruling Against Patents For Vimovo Tablets

Financial news for HZNP dated on 2019-07-18: Horizon Therapeutics Reports FDA Acceptance Of New Drug Application to Make PROCYSBI Available As Oral Granules In Packets

Financial news for HZNP dated on 2019-07-10: Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) For Treatment Of Active Thyroid Eye Disease (TED)

Financial news for HZNP dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for HZNP dated on 2019-06-25: Shares of multiple drugmakers and biotech companies are trading higher after AbbVie announced it will acquire Allergan.

Financial news for HZNP dated on 2019-06-20: Horizon Therapeutics Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA In Combination With Methotrexate To Increase Response Rates And Duration Of Therapy

Financial news for HZNP dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for HZNP dated on 2019-05-29: Horizon Therapeutics plc And Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

Financial news for HZNP dated on 2019-05-15: Horizon Therapeutics Shares Dip Lower, Quickly Rebound From Session Low; Hearing Co. Has Lost Appeal Over 2 Patents On Vimovo Pain Drug

Financial news for HZNP dated on 2019-05-13: Shares of several healthcare companies are trading lower amid continued trade dispute between the US and China. Also, the United States filed a lawsuit against drug manufacturers alleging price fixing.

Financial news for HZNP dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for HZNP dated on 2019-05-08: Horizon Pharma Raises FY19 Sales Guidance From \$1.23B-\$1.25B To \$1.26B-\$1.28B vs \$1.24B Est.

Financial news for HZNP dated on 2019-05-08: Horizon Pharma Q1 EPS \$0.3 Up From \$0.03 YoY, Sales \$280.4M Up From \$223.881M YoY

Financial news for HZNP dated on 2019-05-01: Benzinga's Top Upgrades, Downgrades For May 1, 2019

Financial news for HZNP dated on 2019-05-01: Horizon Pharma shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised the price target from \$21 to \$32.

Financial news for HZNP dated on 2019-05-01: Citigroup Upgrades Horizon Pharma plc - common stock to Buy, Raises Price Target to \$32

Financial news for HZNP dated on 2019-05-01: Citigroup Upgrades Horizon Pharma plc - common stock to Buy

Financial news for HZNP dated on 2019-04-26: The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

Financial news for HZNP dated on 2019-04-21: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for HZNP dated on 2019-03-08: 50 Stocks Moving In Friday's Mid-Day Session

Financial news for HZNP dated on 2019-03-08: UPDATE: Morgan Stanley Upgrades Horizon Pharma As Firm Believes 'the market undervalues HZNP ahead of its mix shift to orphan/rheum diseases'

Financial news for HZNP dated on 2019-03-08: Benzinga's Top Upgrades, Downgrades For March 8, 2019

Financial news for HZNP dated on 2019-03-08: 28 Stocks Moving In Friday's Pre-Market Session

Financial news for HZNP dated on 2019-03-08: Morgan Stanley Upgrades Horizon Pharma to Overweight

Financial news for HZNP dated on 2019-03-07: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for HZNP dated on 2019-03-07: Horizon Pharma Prices 12.244M Share Public Offering of Ordinary Shares @\$24.50/Share

Financial news for HZNP dated on 2019-03-06: Shares of several biotech companies are trading lower after FDA commissioner Scott Gottlieb announced he will resign; he pushed to spur the development of new drugs and with his absence, there is concern on future FDA approvals.

Financial news for HZNP dated on 2019-03-06: Horizon Pharma Exec VP Geoffrey Curtis, Responding To Tues. Evening Chatter Co.'s \$300M Offering Was Cancelled/Delayed, Confirms To Benzinga Co. Has Not Cancelled Its Ordinary Share Offering Announced Mon. Afternoon

Financial news for HZNP dated on 2019-03-06: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for HZNP dated on 2019-03-06: The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

Financial news for HZNP dated on 2019-03-05: IPO Boutique Reports Horizon Pharma Offering Is Being Delayed Due To Late-Breaking Information Regarding The Company

Financial news for HZNP dated on 2019-03-05: Hearing Horizon Pharma Has Cancelled Its \$300M Offering Announced Mon. Afternoon

Financial news for HZNP dated on 2019-03-05: The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings

Financial news for HZNP dated on 2019-03-04: Horizon Pharma Reports \$300M Ordinary Share Offering

Financial news for HZNP dated on 2019-03-04: Horizon Pharma Filing Shows Registration For Ordinary Shares Offering, No Size Disclosed

Financial news for HZNP dated on 2019-03-01: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 1, 2019

Financial news for HZNP dated on 2019-03-01: The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis

Financial news for HZNP dated on 2019-03-01: 75 Biggest Movers From Yesterday

Financial news for HZNP dated on 2019-02-28: Mid-Afternoon Market Update: Box Drops On Weak Forecast; Arcadia Biosciences Shares Gain

Financial news for HZNP dated on 2019-02-28: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for HZNP dated on 2019-02-28: Mid-Day Market Update: Veritiv Falls After Q4 Results; Horizon Pharma Shares Surge

Financial news for HZNP dated on 2019-02-28: Mid-Morning Market Update: Markets Open Lower; J C Penney Profit Beats Expectations

Financial news for HZNP dated on 2019-02-28: Horizon Pharma shares are trading higher after the company said its phase 3 trials for active thyroid eye disease treatment met primary and all secondary endpoints.

Financial news for HZNP dated on 2019-02-28: 34 Stocks Moving In Thursday's Pre-Market Session

Financial news for HZNP dated on 2019-02-28: Horizon Pharma Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) For Active Thyroid Eye Disease (TED) Met Primary And All Secondary Endpoints

Financial news for HZNP dated on 2019-02-27: Horizon Pharma Sees FY19 Sales \$1.23B-\$1.25B vs \$1.24B Est.

Financial news for HZNP dated on 2019-02-27: Horizon Pharma Q4 Adj. EPS \$0.67 Beats \$0.54 Estimate, Sales \$355.543M Beat \$334.22M Estimate

Financial news for HZNP dated on 2019-02-27: Earnings Scheduled For February 27, 2019

Financial news for HZNP dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for HZNP dated on 2019-02-13: 35 Stocks Moving In Wednesday's Pre-Market Session

Financial news for HZNP dated on 2019-01-31: Jim Cramer Shares His Thoughts On Ford, PepsiCo And More

Financial news for HZNP dated on 2019-01-04: Horizon Pharma 8-K Shows Co. Sold Rights To RAVICTI, AMMONAPS Outside North America, Japan To Medical Need Europe For \$35M

Financial news for HZNP dated on 2019-01-03: Horizon Pharma Reports Entered Exclusive Drug Discovery Collab With HemoShear For Gout

Financial news for HZNP dated on 2018-12-27: Horizon Pharma Reports FDA Approval To Expand Age Range For RAVICTI Liquid To Include Newborns

Financial news for HZNP dated on 2018-11-15: 8 Biggest Price Target Changes For Thursday

Financial news for HZNP dated on 2018-11-15: Benzinga's Top Upgrades, Downgrades For November 15, 2018

Financial news for HZNP dated on 2018-11-15: Mizuho Downgrades Horizon Pharma to Neutral, Lowers Price Target to \$21

Financial news for HZNP dated on 2018-11-14: Hearing Novartis AG Has Approached

Horizon Pharma With \$31/Share Takeover Bid; Unconfirmed

Financial news for HZNP dated on 2018-11-08: Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018

Financial news for HZNP dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for HZNP dated on 2018-11-08: 88 Biggest Movers From Yesterday

Financial news for HZNP dated on 2018-11-07: Horizon Pharma Maintains FY2018 Sales of \$1.17B-1.20B vs \$1.18B Est

Financial news for HZNP dated on 2018-11-07: Horizon Pharma, Inc. Q3 EPS \$0.65 Beats \$0.50 Estimate, Sales \$325.311M Beat \$311.85M Estimate

Financial news for HZNP dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for HZNP dated on 2018-11-07: Earnings Scheduled For November 7, 2018

Financial news for HZNP dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for HZNP dated on 2018-10-23: Horizon Shares Down 5.5%; Cowen Notes 2 Recent Disclosures From Co. 'with 1 of the 2 (the release of disappointing competitive data which therefore preserves and secures Krystexxa' place as the leader for years to come) far outweighing...'

Financial news for HZNP dated on 2018-08-10: Stocks Which Set New 52-Week High Yesterday, August 9th

Financial news for HZNP dated on 2018-08-10: The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss

Financial news for HZNP dated on 2018-08-09: Stocks Which Set New 52-Week High Yesterday, August 8th

Financial news for HZNP dated on 2018-08-09: Jefferies Maintains Buy on Horizon Pharma, Raises Price Target to \$23

Financial news for HZNP dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for HZNP dated on 2018-08-08: Stocks Which Set New 52-Week High Yesterday, August 7th

Financial news for HZNP dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for HZNP dated on 2018-08-06: Benzinga's Top Upgrades, Downgrades For August 6, 2018

Financial news for HZNP dated on 2018-08-06: BMO Capital Downgrades Horizon Pharma to Market Perform, Announces \$18 Price Target

Financial news for HZNP dated on 2018-07-25: Clinigen Acquires Global Rights to Imukin from Horizon Pharma; Terms Not Disclosed

Financial news for HZNP dated on 2018-07-16: Horizon Pharma Reports US PTO Issuance Of Added Notices Of Allowance With Claims Covering RAVICTI Oral Liquid

Financial news for HZNP dated on 2018-06-27: Citigroup Downgrades Horizon Pharma to Neutral

Financial news for HZNP dated on 2018-05-31: Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time

Financial news for HZNP dated on 2018-05-30: Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immunet Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Financial news for HZNP dated on 2018-05-09: Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Financial news for HZNP dated on 2018-05-09: Horizon Pharma Raises FY2018 Sales Guidance from \$1.15B-1.18B to \$1.17B-1.20B vs \$1.15B Est., Adj. EBITDA From \$370M-\$395M To \$390M-\$415M

Financial news for HZNP dated on 2018-05-09: Horizon Pharma Raises Outlook

Financial news for HZNP dated on 2018-05-09: Horizon Pharma Q1 EPS \$0.03 Misses \$0.07 Estimate, Sales \$223.881M Miss \$234.17M Estimate

Financial news for HZNP dated on 2018-05-07: Earnings Scheduled For May 7, 2018

Financial news for HZNP dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for HZNP dated on 2018-03-13: Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts

Financial news for HZNP dated on 2018-03-01: Height Securities Sees Regulators Changing Their Approach To Drug Pricing, Cites Horizon Pharma's KRYSTEXXA As Potential Beneficiary

Financial news for HZNP dated on 2018-02-28: Horizon Pharma Sees FY18 Adj. EBITDA \$370M-\$395M, Sales \$1.15B-\$1.18B vs \$1.14B Est.

Financial news for HZNP dated on 2018-02-28: Horizon Pharma Reports Q4 Adj. EPS \$0.29 vs \$0.22 Est., Sales \$274.2M vs \$264.5M Est.

Financial news for HZNP dated on 2018-02-28: Earnings Scheduled For February 28, 2018

Financial news for HZNP dated on 2018-02-27: Horizon Pharma Reports Submission Of sNDA For RAVICTI Oral Liquid

Financial news for HZNP dated on 2018-02-25: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for HZNP dated on 2018-01-12: 33 Stocks Moving In Friday's Mid-Day Session

Financial news for HZNP dated on 2018-01-12: 5 Biggest Price Target Changes For Friday

Financial news for HZNP dated on 2018-01-12: Benzinga's Top Upgrades, Downgrades For January 12, 2018

Financial news for HZNP dated on 2018-01-12: The Market In 5 Minutes: Blockchain Enthusiasm, Facebook's News Feed, Trump's Potty Mouth

Financial news for HZNP dated on 2018-01-12: Mizuho Upgrades Horizon Pharma to Buy from Neutral; Raises PT to \$18 from \$12 -Reuters

Financial news for HZNP dated on 2018-01-08: Horizon Pharma Raises Peak Net Sales Guidance From \$650M To \$1.5B+

Financial news for HZNP dated on 2018-01-08: Horizon Pharma Earlier Announced Licensing Global Rights To MEDI4945 From AstraZeneca, Will Provide Upfront Cash Payment And Future Milestone Payments

Financial news for HZNP dated on 2018-01-02: Several Biotechs Higher Tuesday Amid Jefferies Mention Of Price Increases In Effect; Insys +13.21%, Synergy Pharmaceuticals +6.72%, Allergan +3.22%, Horizon Pharma +0.99%, Supernus Pharma +0.25%, Teva Pharma +0.53%; Collegium An Outlier, Down 0.64%

Financial news for HZNP dated on 2017-12-27: Horizon Pharma Reports FDA Approval To Expand Indication For PROCYSBI Delayed-Release Capsules To Include Children 1 Year Of Age And Older Living With Nephropathic Cystinosis

Financial news for HZNP dated on 2017-12-05: Horizon Pharma Option Alert: Jan, 2019 \$13 Calls Sweep (9) at the Ask: 541 @ \$4.101 vs 327 OI; Ref=\$14.48

Financial news for HZNP dated on 2017-11-30: Horizon Pharma Names Shao-Lee Lin R&D, Chief Scientific Officer

Financial news for HZNP dated on 2017-11-06: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for HZNP dated on 2017-11-06: Horizon Pharma Says Will Present New KRYSTEXXA Data at ACR/ARHP Meeting: 'Analyses further support the efficacy and safety of KRYSTEXXA'

Financial news for HZNP dated on 2017-11-06: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for HZNP dated on 2017-11-06: Horizon Pharma Raises FY17 Adj. EBITDA Guidance To \$350M-\$375M

Financial news for HZNP dated on 2017-11-06: Horizon Pharma Raises FY17 Outlook From \$985M-\$1.02B As Of Jun. 23 To \$1.03B-\$1.05B vs \$1.04B Est.

Financial news for HZNP dated on 2017-11-06: Horizon Pharma Reports Q3 Adj. EBITDA \$108.1M, Adj. EPS \$0.26 vs \$0.22 Est., Sales \$271.6M vs \$259.7M Est.

Financial news for HZNP dated on 2017-11-05: Horizon Pharma Presents Promising Results from Open-Label Study on the Use of PROCYSBI Delayed-Release Capsules in Treatment-Naive Children Younger than 6 Years of Age at #ASN2017

Financial news for HZNP dated on 2017-11-01: Horizon Pharma Pops to High of \$14.08 off of Multiple Call Sweeps

Financial news for HZNP dated on 2017-11-01: Horizon Pharma Option Alert: Nov 17 \$13 Calls Sweep (42) at the Ask: 1606 @ \$1.399 vs 1484 OI; Ref=\$13.85

Financial news for HZNP dated on 2017-10-25: Horizon Pharma Reports First Patient Enrolled In Confirmatory Phase 3 Trial Evaluating Teprotumumab For Treatment Of Moderate-To-Severe Active Thyroid Eye Disease

Financial news for HZNP dated on 2017-09-28: Goldman Sachs Initiates Coverage On Horizon Pharma plc - common stock with Buy Rating, Announces \$16.00 Price Target

Financial news for HZNP dated on 2017-09-26: Horizon Shares Down 4.9% On Lupin vs Horizon Ravicti '559 Patent IPR Final Written Decision

Financial news for HZNP dated on 2017-09-15: Horizon Pharma Option Alert: Nov 17 \$14 Calls Sweep (8) at the Ask: 740 @ \$0.6 vs 295 OI; Ref=\$12.24

Financial news for HZNP dated on 2017-09-15: Hearing Horizon Pharma Considering Sale Of Its Primary Care Unit

Financial news for HZNP dated on 2017-09-14: Watch These 6 Huge Put Purchases In Thursday Trade

Financial news for HZNP dated on 2017-09-13: Benzinga's Option Alert Recap From September 13

Financial news for HZNP dated on 2017-09-13: Horizon Pharma Option Alert: Fri \$14 Puts Sweep (41) at the Ask: 1000 @ \$1.069 vs 279 OI; Ref=\$12.96

Financial news for HZNP dated on 2017-08-14: 13F From Farallon Capital Shows Reduced Stakes In Horizon Pharma, IHS Markit

Financial news for HZNP dated on 2017-08-07: 18 Biggest Mid-Day Gainers For Monday

Financial news for HZNP dated on 2017-08-07: Horizon Pharma Surrenders Some Early Gains After Q2 Beat And Raise

Financial news for HZNP dated on 2017-08-07: Horizon Pharma Raises FY 2017 Guidance to \$1.01B-\$1.045B from \$985M-1.02B vs \$991.2M Est.

Financial news for HZNP dated on 2017-08-07: Horizon Pharma Q2 EPS \$0.41 vs \$0.10 Est., Sales \$289.5M vs \$237.0M Est.

Financial news for HZNP dated on 2017-08-07: Earnings Scheduled For August 7, 2017

Financial news for HZNP dated on 2017-07-13: Watch These 7 Huge Call Purchases In Thursday Trade

Financial news for HZNP dated on 2017-07-12: Benzinga's Option Alert Recap From July 12

Financial news for HZNP dated on 2017-07-12: Horizon Pharma Option Alert: Aug 18 \$11 Calls Sweep (31) at the Ask: 1270 @ \$2.15 vs 792 OI; Ref=\$12.79

Financial news for HZNP dated on 2017-06-27: Horizon Pharma Says a New Jersey Court Upheld Two Patents and Stated That Mylan Would Infringe With At Least 1 Patent with Their Generic Naproxen Products

Financial news for HZNP dated on 2017-06-23: UPDATE: Horizon Pharma Now Sees FY17 Sales \$985M-\$1.02B vs \$990.53M Est.

Financial news for HZNP dated on 2017-06-23: Horizon Pharma Completes Sale Of European Rights To PROCYSBI, Sees FY17 Sales Reduced By \$15M As A Results

Financial news for HZNP dated on 2017-06-19: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for HZNP dated on 2017-06-19: Horizon Pharma Reports Health Canada Approval Of PROCYSBI For Treatment Of Nephropathic Cystinosis

Financial news for HZNP dated on 2017-06-16: Cantor Fitzgerald Initiates Coverage On Horizon Pharma plc - common stock with Overweight Rating, Announces \$13.00 Price Target

Financial news for HZNP dated on 2017-06-14: Horizon Pharma Presents New Data Analyses Showing 'Significant Clinical Benefit' Of KRYSTEXXA

Financial news for HZNP dated on 2017-06-07: Wall Street's M&A Chatter From June 6: Valeant-Bausch & Lomb, Albany Molecular, Horizon Pharma

Financial news for HZNP dated on 2017-06-06: Horizon Shares Spiking Higher After Betaville Report Of Horizon Pharma Exploring A Sale

Financial news for HZNP dated on 2017-06-06: Volume Spike in Horizon Pharma

Financial news for HZNP dated on 2017-05-23: Horizon Pharma Adjusts FY17 GAAP Sales Outlook to \$985M-\$1.02B, Affirms Adj. EBITDA \$315M-\$350M

Financial news for HZNP dated on 2017-05-23: Horizon Pharma Sees FY17 Sales Related to PROCYSBI, QUINSAIR in EMEA Regions Reduced by ~\$15M, Neutral on Adj. EBITDA

Financial news for HZNP dated on 2017-05-23: UPDATE: Terms of Milestone Payments for Horizon Pharma's Sale of PROCYSBI, QUINSAIR Marketing Rights Not Disclosed

Financial news for HZNP dated on 2017-05-23: Horizon Pharma Reports Deal to Sell European Marketing Rights to PROCYSBI Delayed-Release Capsules, QUINSAIR in EMEA to Chiesi for Upfront Payment of \$70M

Financial news for HZNP dated on 2017-05-15: Nuvo Pharma Reports US District Court for New Jersey Upheld Validity of Horizon Pharma's US Patent Covering Pennsaid 2% w/w

Financial news for HZNP dated on 2017-05-15: Horizon Pharma plc Announces District Court Decision to Uphold PENNSAID 2% w/w Patent in Case with Actavis Labs

Financial news for HZNP dated on 2017-05-09: 5 Biggest Price Target Changes For Tuesday

Financial news for HZNP dated on 2017-05-09: Benzinga's Top Upgrades, Downgrades For May 9, 2017

Financial news for HZNP dated on 2017-05-09: Mizuho Downgrades Horizon Pharma plc - common stock to Neutral

Financial news for HZNP dated on 2017-05-08: Mid-Afternoon Market Update: Petmed Rises On Strong Q1 Results; TherapeuticsMD Shares Plunge

Financial news for HZNP dated on 2017-05-08: Martin Shkreli in Facebook Post Says He Likes Horizon Pharma For A Pop, But 'Wouldn't Marry It'; Likes Alexion A Lot On The Pullback

Financial news for HZNP dated on 2017-05-08: 12 Biggest Mid-Day Losers For Monday

Financial news for HZNP dated on 2017-05-08: Mid-Day Market Update: Horizon Pharma Drops After Q1 Miss; SGOCO Group Shares Surge

Financial news for HZNP dated on 2017-05-08: Cowen Out Positive On Horizon, Says Investors Willing To Look Forward Will See Orphan Assets Undervalued, Specialty Products Will Be Managed To Profitability And Sold

Financial news for HZNP dated on 2017-05-08: Horizon Pharma At 2-Year Low After Q1 Miss

Financial news for HZNP dated on 2017-05-08: Mid-Morning Market Update: Markets Edge Lower; Tyson Profit Misses Estimates

Financial news for HZNP dated on 2017-05-08: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for HZNP dated on 2017-05-08: Horizon Pharma Lowers FY 2017 Guidance, Sees Sales \$1.00B-\$1.04B from \$1.24B-\$1.29B vs \$1.26B Est

Financial news for HZNP dated on 2017-05-08: Horizon Pharma Q1 EPS \$0.21 vs \$0.23 Est, Sales \$220.9M vs \$247.9M Est

Financial news for HZNP dated on 2017-05-08: Horizon Pharma to Acquire River Vision

for \$145M Cash

Financial news for HZNP dated on 2017-05-01: Horizon Pharma Says FDA Approves Supplemental NDA to Expand the Age Range for RAVICTI

Financial news for HZNP dated on 2017-03-30: Horizon Pharma plc Reports USPTO Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO

Financial news for HZNP dated on 2017-03-08: Benzinga's Option Alert Recap From March 8

Financial news for HZNP dated on 2017-03-08: Option Alert: Horizon Pharma Apr 17.0 Calls Sweep: 561 @ ASK \$0.35: 561 traded vs 132 OI: Earnings 5/8 Before Open (est) \$15.04 Ref

Financial news for HZNP dated on 2017-02-27: A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Durable-Goods Orders, Home Sales Data

Financial news for HZNP dated on 2017-02-27: Horizon Pharma Sees FY17 Sales \$1.24-\$1.29B vs. \$1.28B Est., Sees FY17 EBITDA \$525-\$575M

Financial news for HZNP dated on 2017-02-27: Horizon Pharma Reports Q4 Adj. EPS \$0.64 vs. \$0.51 Est., Sales \$310.3M vs. \$309M Est.

Financial news for HZNP dated on 2017-02-21: Horizon Pharma Spikes to High of \$17.25 Following Report Co Won Against Kyle Bass IPR Patent Challenge on Vimovo '621 Paten

Financial news for HZNP dated on 2017-01-30: Watch These 8 Huge Call Purchases In Monday Trade

Financial news for HZNP dated on 2017-01-27: Benzinga's Option Alert Recap From January 27

Financial news for HZNP dated on 2017-01-27: Option Alert: Horizon Pharma Feb 18.0 Calls Sweep: 1700 @ ASK \$0.248: 2025 traded vs 14k OI: Earnings 2/27 Before Open (est) \$15.96 Ref

Financial news for HZNP dated on 2017-01-24: Benzinga's Option Alert Recap From January 24

Financial news for HZNP dated on 2017-01-24: Option Alert: Horizon Pharma Mar 17.0 Calls: 2000 @ ASK \$1.30: 2010 traded vs 2012 OI: Earnings 2/27 Before Open (est) \$16.42 Ref

Financial news for HZNP dated on 2017-01-10: Option Alert: Horizon Pharma Jan 18.0 Calls Sweep: 1095 @ ASK \$0.547: 1505 traded vs 1891 OI: Earnings 2/27 Before Open (est) \$17.70 Ref

Financial news for HZNP dated on 2016-12-22: Horizon Pharma Announces U.S. Patent Office Issuance Of Notice Of Allowance With Claims Covering RAVICTI

Financial news for HZNP dated on 2016-12-22: Horizon Pharma plc Announces Availability of QUINSAIR in Canada

Financial news for HZNP dated on 2016-12-22: Horizon Reports Availability Of Quinsair In Canada For Treatment Of Lung Infections From Cystic Fibrosis

Financial news for HZNP dated on 2016-12-16: JMP Remains Positive On Horizon, Reiterates Market Outperform Rating And \$33 PT As Express Scripts Removed Vimovo and Duexis From Their Exclusion Lists

Financial news for HZNP dated on 2016-12-16: Technical Alert: Horizon Pharma Higher After Mizuho Upgrade

Financial news for HZNP dated on 2016-12-16: Horizon Pharma Looking To Finish Strong In 2016

Financial news for HZNP dated on 2016-12-16: The Market In 5 Minutes: Adobe, Oracle Take The Earnings Stage

Financial news for HZNP dated on 2016-12-16: 7 Biggest Price Target Changes For Friday

Financial news for HZNP dated on 2016-12-16: 15 Stocks Moving In Friday's Pre-Market Session

Financial news for HZNP dated on 2016-12-16: Mizuho Upgrades Horizon Pharma plc - common stock to Buy, Raises Target to \$25.00

Financial news for HZNP dated on 2016-12-14: BMO Capital Healthcare Conf. Takes Place Today; Presenters Include Neurocrine Biosciences, Ionis Pharmaceuticals, Horizon Pharma, And Intercept Pharmaceuticals

Financial news for HZNP dated on 2016-12-09: Benzinga's Top Downgrades

Financial news for HZNP dated on 2016-12-09: Mizuho Downgrades Horizon Pharma plc to Neutral

Financial news for HZNP dated on 2016-12-08: Mid-Afternoon Market Update: Dow Up 75 Points; Lululemon Shares Surge On Earnings Beat

Financial news for HZNP dated on 2016-12-08: Hearing UBS Saying Weakness On FA News Is A Buying Opportunity

Financial news for HZNP dated on 2016-12-08: Mid-Morning Market Update: Markets Edge Lower; Ciena Profit Misses Estimates

Financial news for HZNP dated on 2016-12-08: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for HZNP dated on 2016-12-08: Horizon Conf. Call, Says Studies Testing Acctimmune In Cancer To Continue As Planned

Financial news for HZNP dated on 2016-12-08: Horizon Pharma's Topline Phase 3 ACTIMMUNE Results Didn't Meet Primary, Secondary Endpoint

Financial news for HZNP dated on 2016-12-08: Horizon Pharma Shares Open Down ~18%

Financial news for HZNP dated on 2016-12-08: Horizon Pharma to Resume Trading at 7:30am

Financial news for HZNP dated on 2016-12-08: Horizon Pharma plc Announces Topline Results from Phase 3 Study of ACTIMMUNE, Did Not Meet Primary & Secondary Endpoint

Financial news for HZNP dated on 2016-12-07: Swedish Orphan Biovitrum Says Signs 5-Year Distribution Agreement With Horizon Pharma

Financial news for HZNP dated on 2016-11-28: Citi: Buy Horizon Pharma

Financial news for HZNP dated on 2016-11-28: Citigroup Reinstates Horizon Pharma at Buy

Financial news for HZNP dated on 2016-11-27: 5 BioPharma Catalysts Expected Around Christmas

Financial news for HZNP dated on 2016-11-17: Jefferies London Health Care Conference Continues Today

Financial news for HZNP dated on 2016-11-07: The Market In 5 Minutes: Stock Futures Boosted By FBI's Latest Clinton News

Financial news for HZNP dated on 2016-11-07: Horizon Sees FY16 Rev. \$1.045-\$1.05B vs. Est. \$1.03B

Financial news for HZNP dated on 2016-11-07: Horizon Pharma Reports Q3 EPS \$0.70 vs. Est. \$0.63, Rev. \$273.7M vs. Est. \$270M

Financial news for HZNP dated on 2016-11-03: UPDATE: Doc from Patent Judge Shows 'we determine that Par has not proved by a preponderance of the evidence that claims 1-12 are unpatentable.'

Financial news for HZNP dated on 2016-11-03: Horizon Pharma Shares Up ~\$0.15 Over Last min as Traders Passing Around Filing from Patent Judge Related to Par Pharm, Lupin v. Horizon

Financial news for HZNP dated on 2016-11-01: Watch Shares Of Horizon Pharma, Mallinckrodt, Endo International, Depomed, In Sympathy To Dow Jones Report of Valeant Selling Salix Unit

Financial news for HZNP dated on 2016-11-01: Horizon Pharma Spikes to High of \$17.18 on Volume

Financial news for HZNP dated on 2016-10-25: UPDATE: Horizon Pharma Affirms FY16 Adj. EBITDA Outlook ~\$450M-\$460M

Financial news for HZNP dated on 2016-10-25: UPDATE: Horizon Pharma Raises FY16 Adj. Sales Outlook to ~\$1.045B-\$1.05B vs \$1.03B Est.

Financial news for HZNP dated on 2016-10-25: UPDATE: Horizon Pharma Raises FY16 GAAP Sales Outlook to ~\$980M-\$985M

Financial news for HZNP dated on 2016-10-25: Horizon Pharma Raises FY16 Sales Outlook, Affirms Adj. EBITDA Outlook Following Raptor Pharma

Financial news for HZNP dated on 2016-10-12: Earnings Season On Deck: How Has Q3 Guidance Looked So Far?

Financial news for HZNP dated on 2016-10-11: 8-K from Horizon Pharma Shows Expectation for Q3 Adj. Sales \$272M-\$274M vs \$272.4M Est., Adj. EBITDA in \$139M-\$141M Range

Financial news for HZNP dated on 2016-10-11: Rich Ross Shares His Biotech Trades

Financial news for HZNP dated on 2016-09-30: Horizon Pharma To Post Double-Digits Returns, Vetr Crowd Believes

Financial news for HZNP dated on 2016-09-29: Horizon Pharma Enters Into Settlement Agreement With Express Scripts, To Pay \$65M; 50% Of Installment To Be Paid In Q4, With 25% In The Following Q1, Q2 Quarters Of 2017

Financial news for HZNP dated on 2016-09-29: Horizon Pharma plc Gives Update on PBM Formulary Status for Primary Care Medicines, Secures Formulary Status With Prime Therapeutics For Primary Care Medicines

Financial news for HZNP dated on 2016-09-27: The Drug Price Increase Debate: Separating The Winners From The Losers

Financial news for HZNP dated on 2016-09-16: Benzinga's Top Downgrades

Financial news for HZNP dated on 2016-09-16: Cowen & Co. Downgrades Horizon Pharma to Market Perform

Financial news for HZNP dated on 2016-09-12: Benzinga's M&A Chatter for Monday September 12, 2016

Financial news for HZNP dated on 2016-09-12: Mid-Afternoon Market Update: Dow Surges Over 200 Points; Geron Shares Tumble

Financial news for HZNP dated on 2016-09-12: 12 Biggest Mid-Day Gainers For Monday

Financial news for HZNP dated on 2016-09-12: Mid-Day Market Update: American Farmland Gains Following Merger News; RetailMeNot Shares Drop

Financial news for HZNP dated on 2016-09-12: Shkreli Thinks Raptor Pharmaceutical's Valuation Was Too Low

Financial news for HZNP dated on 2016-09-12: Mid-Morning Market Update: Markets Rise; Horizon Pharma To Buy Raptor Pharmaceutical For \$9/Share

Financial news for HZNP dated on 2016-09-12: The Market In 5 Minutes: Hillary Clinton Falls Ill With The Global Stock Markets

Financial news for HZNP dated on 2016-09-12: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for HZNP dated on 2016-09-12: Raptor Jumps 20% After Horizon Pharma's \$800 Million Takeover Agreement

Financial news for HZNP dated on 2016-09-12: Raptor Pharmaceutical to Resume at 7:30 AM ET

Financial news for HZNP dated on 2016-09-12: Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. For \$9/Share Cash; For Implied Equity Value Of ~\$800M

Financial news for HZNP dated on 2016-09-07: Goldman's 7 Favorite Biotech Ideas For 2016

Financial news for HZNP dated on 2016-09-07: Horizon Pharma An Attractive Sum-Of-The-Parts Story, Says Goldman

Financial news for HZNP dated on 2016-08-25: Watch These 7 Huge Call Purchases In Thursday Trade

Financial news for HZNP dated on 2016-08-24: Option Alert: HZNP Jan17 24.0 Calls: 1500 @ ASK \$3.10: 3002 traded vs 25k OI: \$21.19 Ref

Financial news for HZNP dated on 2016-08-17: Option Alert: HZNP Sep16 23.0 Calls:

3000 @ ASK \$0.90: 3014 traded vs 679 OI: \$22.22 Ref

Financial news for HZNP dated on 2016-08-08: 15 Biggest Mid-Day Gainers For Monday

Financial news for HZNP dated on 2016-08-08: Benzinga's Volume Movers

Financial news for HZNP dated on 2016-08-08: 11 Stocks Moving In Monday's Pre-Market Session

Financial news for HZNP dated on 2016-08-08: Horizon Sees FY16 Rev. \$1.025-\$1.05B vs. Est. \$1.01B, Adj. EBITDA \$495-\$510M

Financial news for HZNP dated on 2016-08-08: Horizon Pharma Reports Q2 Adj. EPS \$0.62 vs. Est. \$0.50, Rev. \$257.4M vs. Est. \$234.8M

Financial news for HZNP dated on 2016-08-08: Earnings Scheduled For August 8, 2016

Financial news for HZNP dated on 2016-08-04: Option Alert: HZNP Aug16 24.0 Calls Sweep: 1000 @ ASK \$0.35: 1000 traded vs 1044 OI: Earnings 8/8 Before Open \$19.57 Ref

Financial news for HZNP dated on 2016-08-02: Horizon Pharma Says Secured Covered Status for DUEXIS, VIMOVO with CVS/Caremark Beginning January 1, 2017

Financial news for HZNP dated on 2016-08-02: Watch These 10 Huge Call Purchases In Tuesday Trade

Financial news for HZNP dated on 2016-08-01: UPDATE: Horizon Says 'continues to have discussions with Express Scripts and sees a potential pathway, while not guaranteed...'

Financial news for HZNP dated on 2016-08-01: 8-K from Horizon Pharma Shows Co. Has Recognized Express Scripts Published Formulary Exclusion List Which Includes DUEXIS, VIMOVO

Financial news for HZNP dated on 2016-08-01: Horizon Pharma Shares Plunge Into Negative Territory, Now Down 5%; Traders Attributing Weakness to Concern Two Drugs Might Not Be Included on Express Scripts List of Covered Drugs

Financial news for HZNP dated on 2016-08-01: Option Alert: HZNP Aug16 20.0 Calls Sweep: 1000 @ ASK \$0.85: 5511 traded vs 15k OI: Earnings 8/8 Before Open \$17.74 Ref

Financial news for HZNP dated on 2016-08-01: Horizon Pharma Sells off to Low of \$18.62 on Volume

Financial news for HZNP dated on 2016-07-27: Option Alert: HZNP Aug16 20.0 Calls Sweep: 956 @ ASK \$1.40: 6852 traded vs 2626 OI: Earnings 8/8 Before Open \$19.68 Ref

Financial news for HZNP dated on 2016-07-11: The Story Of Horizon Pharma And Morgan Stanley's Upgrade

Financial news for HZNP dated on 2016-07-11: Morgan Stanley Upgrades Horizon Pharma to Equal-weight, Maintains \$24.00 PT

Financial news for HZNP dated on 2016-06-29: 4 Reasons To Own Horizon Pharma Shares

Financial news for HZNP dated on 2016-06-29: Horizon Pharma Reports Submission of sNDA for RAVICTI Liquid for Expansion of Age Range for Mgmt of Urea Cycle Disorders

Financial news for HZNP dated on 2016-06-29: BMO Capital Initiates Coverage on Horizon Pharma at Outperform

Financial news for HZNP dated on 2016-06-28: Horizon Pharma Said to Hire Bank of America to Explore Potential Stake Sale -Reuters

Financial news for HZNP dated on 2016-06-06: Goldman Initiates Specialty Pharma At Neutral, Highlights 'A Confluence Of Concerns'

Financial news for HZNP dated on 2016-06-06: Goldman Likes Horizon Pharma's Emerging Orphan Franchise, Starts At Buy

Financial news for HZNP dated on 2016-06-06: Goldman Sachs Initiates Coverage on Horizon Pharma at Buy, Announces \$24.00 PT

Financial news for HZNP dated on 2016-06-01: FBR Midday Desk Comments Note Biotech Flows Are Beginning To Wane Following ASCO Over Weekend, Says Data Being Met With Aggressive Short Covering

Financial news for HZNP dated on 2016-06-01: Horizon Pharma Announces USPTO Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO Delayed Release Tablets

Financial news for HZNP dated on 2016-05-19: Amid Wage Disparities And Political Concerns Over Jobs, Top CEOs Bring In Beaucoup Incomes

Financial news for HZNP dated on 2016-05-19: Horizon Pharma Will Buy Global Rights to Interferon Gamma-1b from Boehringer Ingelheim for EUR5M and EUR20M Upon Closing for the Rights

Financial news for HZNP dated on 2016-05-12: Horizon Pharma Reverses Earlier Gains Following Patent Litigation Settlement

Financial news for HZNP dated on 2016-05-12: Horizon Pharma Reports Settlement of PENNSAID 2% w/w Patent Litigation with Teligent

Financial news for HZNP dated on 2016-05-11: Option Alert: HZNP Aug16 17.0 Calls: 5000 @ ASK \$1.20: 5000 traded vs 445 OI: \$14.21 Ref

Financial news for HZNP dated on 2016-05-11: Horizon Pharma Reports US PTO Issuance of Added Notice of Allowance with Claims Covering KRYSTEXXA

Financial news for HZNP dated on 2016-05-11: Horizon Pharma plc Reports the U.S. Patent and Trademark Office Issuance of Additional Notice of Allowance With Claims Covering KRYSTEXXA

Financial news for HZNP dated on 2016-05-09: Mid-Afternoon Market Update: Crude Oil Down Over 2.5%; Horizon Pharma Shares Rise Following Earnings Beat

Financial news for HZNP dated on 2016-05-09: Mid-Day Market Update: TETRA Technologies Drops Following Weak Results; Krispy Kreme Shares Spike Higher

Financial news for HZNP dated on 2016-05-09: Mid-Morning Market Update: Markets Edge Higher; Tyson Foods Tops Q2 Estimates

Financial news for HZNP dated on 2016-05-09: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for HZNP dated on 2016-05-09: Horizon Pharma Sees FY16 Rev. \$1.02-\$1.05B vs. Est. \$1.00B

Financial news for HZNP dated on 2016-05-09: Horizon Pharma Reports Q1 EPS \$0.34 vs. Est. \$0.30, Rev. \$204.7M vs. Est. \$197.7M

Financial news for HZNP dated on 2016-05-05: Horizon Pharma plc Completes Target Enrollment of 90 Patients for Phase 3 Trial of ACTIMMUNE(R) (interferon gamma-1b) for the Treatment of People With Friedreich's Ataxia

Financial news for HZNP dated on 2016-05-04: Starboard's Smith Says Depomed Did Not Engage With Horizon Pharma, Took Highly Aggressive 10% Poison Pill

Financial news for HZNP dated on 2016-05-04: Ira Sohn Conference 2016: The Live Blog

Financial news for HZNP dated on 2016-04-27: Jim Cramer Gives His Opinion On Horizon Pharma, Lululemon And Harley-Davidson

Financial news for HZNP dated on 2016-04-25: Horizon Pharma Announces Settlement with Patient for Pennsaid, Horizon Can Make Generic

Financial news for HZNP dated on 2016-04-13: Horizon Pharma Starts To Recover; Vetr Crowd Upgrades Stock

Financial news for HZNP dated on 2016-04-12: Mid-Afternoon Market Update: Crude Oil Up 4.5%; Horizon Pharma Shares Tumble

Financial news for HZNP dated on 2016-04-12: This Explains Horizon Pharma's 25% Plunge

Financial news for HZNP dated on 2016-04-12: Mid-Day Market Update: Dow Jumps 150 Points; Juniper Shares Drop On Weak Forecast

Financial news for HZNP dated on 2016-04-12: Horizon Pharma Shares Trading Down \$3.72 At \$14.49/Share, Falling 20% In Morning Trading

Financial news for HZNP dated on 2016-04-12: Mid-Morning Market Update: Markets Open Higher; Alcoa Revenue Misses Views

Financial news for HZNP dated on 2016-04-12: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for HZNP dated on 2016-04-12: Horizon Pharma Sees FY16 Rev. \$1.025-\$1.05B vs. Est. \$1.03B, Adj. EBITDA \$505-\$520M

Financial news for HZNP dated on 2016-04-12: Horizon Pharma Requests Approval For 16M Buyback

Financial news for HZNP dated on 2016-04-12: Horizon Pharma Releases Investor Presentation

Financial news for HZNP dated on 2016-04-04: Disney, Tesla And 6 Other Stocks Moving In Monday's After-Hours Session

Financial news for HZNP dated on 2016-03-21: Mid-Day Market Update: Affymetrix Stock Drops; Valeant Shares Spike Higher

Financial news for HZNP dated on 2016-03-21: Mid-Morning Market Update: Markets Edge Lower; Sherwin-Williams To Buy Valspar For \$113/Share

Financial news for HZNP dated on 2016-03-21: Horizon Pharma Receives Health Canada Approval For RAVICTI Oral Liquid

Financial news for HZNP dated on 2016-03-18: Shares of Horizon Pharma Selloff to Low of \$13.92; May be Attributed to Cautious Bernstein Note

Financial news for HZNP dated on 2016-03-18: Bernstein Note Out Saying Bernstein Next 'Bad Actor' To Be Targeted After Valeant'; Mentions Horizon and Galderma

Financial news for HZNP dated on 2016-03-17: Option Alert: HZNP Apr16 14.0 Puts Sweep: 1355 @ ASK \$1.50: 2075 traded vs 534 OI: \$14.25 Ref

Financial news for HZNP dated on 2016-03-17: Mid-Morning Market Update: Markets Mostly Lower; Michaels Tops Q4 Expectations

Financial news for HZNP dated on 2016-03-16: Option Alert: HZNP May16 17.0 Calls: 10000 @ ASK \$1.75: 12k traded vs 151 OI: \$15.31 Ref

Financial news for HZNP dated on 2016-03-16: Horizon Pharma Reports US PTO Issued Added Notice of Allowance with Claims Covering RAVICTI Oral Liquid

Financial news for HZNP dated on 2016-03-14: Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) Delayed Release Tablets

Financial news for HZNP dated on 2016-03-02: Horizon Pharma Reports US PTO Has Issued Added Notice of Allowance Related to PENNSAID 2% w/w

Financial news for HZNP dated on 2016-02-29: Earnings Recap For February 29: Lumber Liquidators, Taser & More

Financial news for HZNP dated on 2016-02-29: Mid-Afternoon Market Update: Stocks Turn Lower; BroadSoft Shares Rise On Earnings Beat

Financial news for HZNP dated on 2016-02-29: Horizon Pharma Defended At UBS, Maintains Buys AND \$39 PT, Says 'weakness creates buying opportunity'

Financial news for HZNP dated on 2016-02-29: Mid-Day Market Update: US Stocks Gain; United Natural Foods Shares Slide Following Weak Forecast

Financial news for HZNP dated on 2016-02-29: Mid-Morning Market Update: Markets Mostly Lower; Lumber Liquidators Misses Q4 Estimates

Financial news for HZNP dated on 2016-02-29: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for HZNP dated on 2016-02-29: Horizon Pharma Reports Q4 Adj. EPS \$0.63 vs \$0.62 Est., Sales \$244.5M vs \$240.8M ESs.

Financial news for HZNP dated on 2016-02-29: Earnings Scheduled For February 29, 2016

Financial news for HZNP dated on 2016-02-22: Horizon Pharma Announces That Health Canada Determines RAVICTI Oral Liquid Is Eligible for Data Protection

Financial news for HZNP dated on 2016-02-16: Pozen, Egalet Could be Potential Partners for Struggling Biotech Companies -Reuters

Financial news for HZNP dated on 2016-02-03: Horizon Pharma Spikes to High on Volume

Financial news for HZNP dated on 2016-02-03: Horizon Pharma Shares Spiking

Financial news for HZNP dated on 2016-01-19: Benzinga's Top Initiations

Financial news for HZNP dated on 2016-01-19: Jefferies Initiates Coverage on Horizon Pharma at Buy, Announces \$31.00 PT

Financial news for HZNP dated on 2016-01-12: Mid-Morning Market Update: Markets Open Higher; Alcoa Profit Tops Views

Financial news for HZNP dated on 2016-01-12: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2016-01-12: Horizon Pharma Sees FY2016 Sales \$1.02B-1.05B vs \$998.82M Est

Financial news for HZNP dated on 2016-01-08: Here Are The Top Performing Vetr Crowd Members

Financial news for HZNP dated on 2016-01-04: UPDATE: Horizon Pharma Says US PTO Allowance Represents Fifth US Patent to be Listed in Orange Book for RAVICTI

Financial news for HZNP dated on 2016-01-04: Horizon Pharma Shares Indicated Lower; Co. Recently Announces US PTO Issuance of Added Notice of Allowance with Claims Covering RAVICTI Oral Liquid

Financial news for HZNP dated on 2016-01-02: Kyle Bass Explains The 'Patent Trolls' Situation In The Pharma Industry

Financial news for HZNP dated on 2015-12-31: Option Alert: HZNP Jan16 22.0 Puts Sweep: 2202 @ ASK \$1.45: 2205 traded vs 885 OI: \$22.14 Ref

Financial news for HZNP dated on 2015-12-17: Goldman Sachs Initiates Coverage on Horizon Pharma at Buy, Announces \$29.00 PT

Financial news for HZNP dated on 2015-12-16: Jim Cramer Shares His Thoughts On Horizon Pharma, Ambarella, Intel And Lam Research

Financial news for HZNP dated on 2015-12-14: Brean Reiterates Buy On Horizon Pharma, Likes Crealta Deal

Financial news for HZNP dated on 2015-12-14: Horizon Pharma, Fox Chase Cancer Center Temple Health Start Phase 1 Study Of ACTIMMUNE In Combo With Nivolumab In Patients With Advanced Solid Tumors

Financial news for HZNP dated on 2015-12-11: Horizon Pharma To Acquire Crealta Holdings For \$510M Cash, Transaction To Add \$70-\$80M In Sales

Financial news for HZNP dated on 2015-12-11: Horizon Pharma Halted, News Pending

Financial news for HZNP dated on 2015-12-10: Option Alert: HZNP Dec15 21.0 Calls Sweep: 5000 @ ASK \$0.84: 5055 traded vs 1101 OI: \$20.39 Ref

Financial news for HZNP dated on 2015-12-03: What Should Worry You About Horizon Pharma's Long-Term Business

Financial news for HZNP dated on 2015-12-03: Morgan Stanley Assumes Horizon Pharma at Underweight, Announces \$23.00 PT

Financial news for HZNP dated on 2015-11-30: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for HZNP dated on 2015-11-30: Horizon Pharma plc Receives European Commission Approval for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Two Months of Age and Older

Financial news for HZNP dated on 2015-11-20: Morning Market Losers

Financial news for HZNP dated on 2015-11-20: Benzinga's Top #PreMarket Losers

Financial news for HZNP dated on 2015-11-11: Shares of Horizon Pharma Spike Away from \$18 Level as Hearing Stifel Issuing Mid-Day Defense on Name

Financial news for HZNP dated on 2015-11-11: Mid-Day Market Update: Crude Oil Down 2%; Roundy's Shares Gain On Acquisition News

Financial news for HZNP dated on 2015-11-11: Mid-Morning Market Update: Markets Edge Lower; Macy's Lowers Full-Year Forecast

Financial news for HZNP dated on 2015-11-11: Morning Market Losers

Financial news for HZNP dated on 2015-11-11: Benzinga's Top #PreMarket Losers

Financial news for HZNP dated on 2015-11-11: Horizon Pharma Responds to Express Scripts Lawsuit, Recent Allegations

Financial news for HZNP dated on 2015-11-09: Mid-Morning Market Update: Markets Open Lower; Priceline Issues Weak Forecast

Financial news for HZNP dated on 2015-11-09: Morning Market Gainers

Financial news for HZNP dated on 2015-11-09: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2015-11-09: Horizon Pharma Sees FY16 Sales Up 25+% to \$950M-\$975M vs \$886M Est., FY20 Sales \$800M-\$1b

Financial news for HZNP dated on 2015-11-06: Morning Market Gainers

Financial news for HZNP dated on 2015-11-06: Option Alert: \$HZNP Nov \$22 Call Sweep; 1980 Contracts @Ask @\$0.45

Financial news for HZNP dated on 2015-11-06: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2015-11-06: Horizon Pharma +18% Premarket on Strong Earnings, Guidance

Financial news for HZNP dated on 2015-11-06: Horizon Pharma Raises FY15 Sales Guidance From \$660M-\$680M To \$750M-\$760M

Financial news for HZNP dated on 2015-11-06: Horizon Pharma Reports Q3 EPS \$0.70 vs. Est. \$0.40, Rev. \$226.5M vs. Est. \$185.74M

Financial news for HZNP dated on 2015-11-06: Earnings Scheduled For November 6, 2015

Financial news for HZNP dated on 2015-11-04: Shares of Horizon Pharma Dip Below \$16.75 Resistance Level, Down \$0.40+ Over Last Min

Financial news for HZNP dated on 2015-10-28: Lone Pine To Investors: We Had A Tough Third Quarter

Financial news for HZNP dated on 2015-10-27: Horizon Pharma plc Reports the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO Delayed Release Tablets

Financial news for HZNP dated on 2015-10-26: Horizon Pharma plc Extends Offer to Acquire Depomed, Inc.

Financial news for HZNP dated on 2015-10-26: Benzinga's Top #PreMarket Losers

Financial news for HZNP dated on 2015-10-22: BZ NOTE: Horizon Highlights, "Horizon does not own or have an ownership stake in any pharmacy and does not possess an option to purchase any pharmacy"

Financial news for HZNP dated on 2015-10-22: Horizon Pharma Corrects Misinformation in the Marketplace

Financial news for HZNP dated on 2015-10-22: FDA Ruling Shakes Up Biotech: Gilead, AbbVie And More

Financial news for HZNP dated on 2015-10-22: Noted Biotech Analyst Doesn't Think Valeant And Horizon Are Frauds, But Did Push A Line

Financial news for HZNP dated on 2015-10-22: Horizon Pharma Spiking On Volume Following Mention On Bloomberg In Interview With Citron Research Discussing Valeant Pharma And Phantom Pharmacies

Financial news for HZNP dated on 2015-10-22: Depomed Validates Horizon Pharma Rejection Offer

Financial news for HZNP dated on 2015-10-22: Morning Market Losers

Financial news for HZNP dated on 2015-10-22: Depomed Comments on Recent Reports Regarding Horizon Pharma's Business Model, Reports Confirms Concerns Raised By Depomed's Board In Rejecting Horizon's Unsolicited Exchange Offer

Financial news for HZNP dated on 2015-10-22: Benzinga's Top #PreMarket Losers

Financial news for HZNP dated on 2015-10-22: Horizon Pharma Reports US PTO Issuance

of Added Notice of Allowance with Claims Covering PENNSAID 2%

Financial news for HZNP dated on 2015-10-21: Biotech Names Like Horizon, Pacira, Akorn, Shire, Mallinckrodt Volatile On Citron Report & Subsequent Valeant Pharma. Press Release

Financial news for HZNP dated on 2015-10-20: Mid-Afternoon Market Update: Hexcel Drops On Earnings Miss; Weight Watchers Shares Spike Higher

Financial news for HZNP dated on 2015-10-20: Mid-Day Market Update: Weight Watchers Surges Following Barclays Upgrade; Rambus Shares Slide

Financial news for HZNP dated on 2015-10-20: Morning Market Losers

Financial news for HZNP dated on 2015-10-20: Benzinga's Top #PreMarket Losers

Financial news for HZNP dated on 2015-10-09: How To Invest During Biotech's Latest Crisis

Financial news for HZNP dated on 2015-10-09: Benzinga's Top Initiations

Financial news for HZNP dated on 2015-10-09: Mizuho Securities Initiates Coverage on Horizon Pharma at Buy, Announces \$32.00 PT

Financial news for HZNP dated on 2015-10-07: Horizon Pharma Announces Three Leading Proxy Advisory Firms Recommend Depomed Shareholders Provide Consent FOR Special Meetings Request

Financial news for HZNP dated on 2015-10-02: Horizon Pharma Announces Settlement of Rayos

Financial news for HZNP dated on 2015-09-28: Horizon Pharma Announces ISS Recommends Depomed Holders Provide Consent FOR Two Special Meeting Requests

Financial news for HZNP dated on 2015-09-25: 15 Stocks Moving In Friday's After-Hours Trading

Financial news for HZNP dated on 2015-09-25: Horizon Pharma Reports CHMP Opinion for RAVICTI Oral Liquid for Treatment of Urea Cycle Disorders in Patients Greater Than Two Months of Age

Financial news for HZNP dated on 2015-09-25: Jim Cramer Shares His Thoughts On Horizon Pharma And SUPERVALU

Financial news for HZNP dated on 2015-09-23: Stifel Reiterates Horizon Pharma As 'Select List' Pick, Sees 'Buying Opportunity In Multiple Misguided Reactions'

Financial news for HZNP dated on 2015-09-23: Stifel Analysts Believe Horizon Pharma. Pressure From PME "optimization" And Concern Around Prescription Trends & Drug Pricing in Biopharma. Is Largely Overdone, Reiterates Horizon As Select List Pick; Buy Rating

Financial news for HZNP dated on 2015-09-23: Stifel on Horizon Pharma: 'Buying Opportunity in Multiple Misguided Reactions'; Reiterated as 'Select List' Pick, Buy Rating, \$45 Price Target

Financial news for HZNP dated on 2015-09-22: Option Alert: \$HZNP Oct \$29 Call; 1940 Contracts @Ask @\$0.65; Now \$25.53

Financial news for HZNP dated on 2015-09-22: Benzinga's Top Downgrades

Financial news for HZNP dated on 2015-09-22: Premium No Longer Deserved? Why Brean's Difei Yang Is Downgrading Horizon Pharma

Financial news for HZNP dated on 2015-09-22: UPDATE: Brean Cuts Horizon Pharma; Firm's Difei Yang Believes 'Premium Valuation in HZNP No Longer Justified'

Financial news for HZNP dated on 2015-09-22: Brean Capital Downgrades Horizon Pharma to Hold, Removes \$40.00 PT

Financial news for HZNP dated on 2015-09-15: 8-K from Horizon Pharma Shows Co. Entered Settlement Deal Related to Infringement Litigation Against Taro Pharma

Financial news for HZNP dated on 2015-09-14: Depomed's Board of Directors Rejects Horizon Pharma plc's Unsolicited Exchange Offer

Financial news for HZNP dated on 2015-09-08: Depomed Issues Statement On Horizon Pharma Unsolicited Exchange Offer

Financial news for HZNP dated on 2015-09-08: Horizon Pharma Announces Commencement of Exchange to Acquire Depomed

Financial news for HZNP dated on 2015-08-31: Depomed 8-K Shows Letter Sent To Horizon Pharma, Says Record Date Re: Horizon Request To be Sent Oct 29th

Financial news for HZNP dated on 2015-08-28: This Analyst Loves Depomed And Its Nucynta Prescription

Financial news for HZNP dated on 2015-08-21: Depomed Sent Letter to Horizon Pharma in Connection with Horizon's Requests for Depomed to Set Record Date to Determine Shareholders Entitled to Request Special Shareholders Meeting

Financial news for HZNP dated on 2015-08-19: Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for Depomed's Board

Financial news for HZNP dated on 2015-08-13: UPDATE: Depomed Points Out Horizon's Offer Has Current Value Below \$31/Share, Less Than Prior Proposal

Financial news for HZNP dated on 2015-08-13: Depomed Comments On Horizon Pharma Letter

Financial news for HZNP dated on 2015-08-13: Horizon Pharma Issues Letter to Depomed: Says Stands by Bid for Shares at \$33/Share

Financial news for HZNP dated on 2015-08-07: Depomed Issues Letter to Horizon Pharma

Financial news for HZNP dated on 2015-08-03: Last Week's Top Hedge Fund Moves: D.E. Shaw, OZ Management & Lone Pine

Financial news for HZNP dated on 2015-08-03: Depomed to File Complaint Today against Horizon Seeking Injunction to Prevent Horizon from Unlawfully Exploiting Depomed's Highly Confidential Trade Secret Data

Financial news for HZNP dated on 2015-07-30: Depomed Rejected Horizon Pharma's Takeout Bid, But Still Trades As If M&A Is Happening

Financial news for HZNP dated on 2015-07-29: Depomed Rejects Horizon Pharma's Latest Proposal as 'Inadequate'

Financial news for HZNP dated on 2015-07-27: 13G from Lone Pine Capital on Horizon Pharma Shows New 5.4% Stake

Financial news for HZNP dated on 2015-07-21: Benzinga's M&A Chatter for Tuesday July 21, 2015

Financial news for HZNP dated on 2015-07-21: Depomed Confirms Receipt of Unsolicited Proposal From Horizon Pharma

Financial news for HZNP dated on 2015-07-21: Piper Jaffray: Horizon Pharma Still Has Room For Value Creation, Target Hiked To \$48

Financial news for HZNP dated on 2015-07-21: Horizon Pharma Announces Increased Offer for Depomed from \$29.25 to \$33/Share

Financial news for HZNP dated on 2015-07-20: Morning Market Gainers

Financial news for HZNP dated on 2015-07-20: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2015-07-20: Horizon Pharma Expects Q2 Sales \$170M to \$172M

Financial news for HZNP dated on 2015-07-13: Horizon Pharma Issues Response to Depomed's Adoption of Poison Pill: 'Very Disappointed,' Urging Board to 'Stop Taking Actions to Frustrate the Will of Holders'

Financial news for HZNP dated on 2015-07-09: New Studies And Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials

Financial news for HZNP dated on 2015-07-09: Horizon Pharma Names Tina Ventura VP, IR

Financial news for HZNP dated on 2015-07-08: Tuesday, Wednesday's Economic Conditions And Major Market Movers: China Continues To Decline, Greece Continues Delay

Financial news for HZNP dated on 2015-07-08: Keep an Eye on These Stocks for July 8, 2015

Financial news for HZNP dated on 2015-07-07: Benzinga's M&A Chatter for Tuesday July

7, 2015

Financial news for HZNP dated on 2015-07-07: Mid-Afternoon Market Update: A Schulman Slips After Q3 Results; Plug Power Shares Spike Higher

Financial news for HZNP dated on 2015-07-07: Mid-Day Market Update: Dow Tumbles 150 Points; Advanced Micro Devices Shares Slide On Nasty Guidance

Financial news for HZNP dated on 2015-07-07: Mid-Morning Market Update: Markets Drop; Horizon Pharma Proposes To Buy Depomed for \$29.25/Share

Financial news for HZNP dated on 2015-07-07: Benzinga's Volume Movers

Financial news for HZNP dated on 2015-07-07: Depomed Confirms Receipt Of Unsolicited Proposal From Horizon Pharma For All-Stock Transaction Valued At \$29.25/Share

Financial news for HZNP dated on 2015-07-07: Stocks Hitting 52-Week Highs

Financial news for HZNP dated on 2015-07-07: Morning Market Losers

Financial news for HZNP dated on 2015-07-07: Morning Market Gainers

Financial news for HZNP dated on 2015-07-07: Horizon CEO Says We are Offering a Fair Price for Depomed -Reuters

Financial news for HZNP dated on 2015-07-07: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2015-07-07: UPDATE: Horizon Pharma Acquisition of Depomed is a Proposal to Shareholders, Not Firm Deal

Financial news for HZNP dated on 2015-07-07: Horizon Pharma All Stock Depomed Acquisition Suggests 41.7% Premium, Values Company at \$3B

Financial news for HZNP dated on 2015-07-07: Horizon Pharma Announces Acquisition of Depomed For \$29.25, All Stock

Financial news for HZNP dated on 2015-07-06: US Stock Futures Drop Ahead Of Economic Data

Financial news for HZNP dated on 2015-07-06: Horizon Pharma plc Files Patent Infringement Lawsuits Against Five Companies for Filing Abbreviated New Drug Applications for PENNSAID 2%

Financial news for HZNP dated on 2015-07-02: Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID

Financial news for HZNP dated on 2015-06-11: Benzinga's Top Initiations

Financial news for HZNP dated on 2015-06-11: Morgan Stanley Initiates Horizon Pharma With Overweight

Financial news for HZNP dated on 2015-06-11: Morgan Stanley Initiates Coverage on Horizon Pharma at Overweight, Announces \$38.00 PT

Financial news for HZNP dated on 2015-06-05: Horizon Pharma plc Initiates Phase 3 Trial of ACTIMMUNE(R) (interferon gamma-1b) for the Treatment of People With Friedreich's Ataxia

Financial news for HZNP dated on 2015-05-22: Benzinga's Top Initiations

Financial news for HZNP dated on 2015-05-22: Leerink Swann Initiates Horizon Pharma With Outperform

Financial news for HZNP dated on 2015-05-22: Leerink Swann Initiates Coverage on Horizon Pharma at Outperform, Announces \$37.00 PT

Financial news for HZNP dated on 2015-05-08: Horizon Pharma Expecting FY15 Sales \$590M-\$610M vs \$538.76M

Financial news for HZNP dated on 2015-05-08: Horizon Pharma Q1 EPS \$0.21 vs \$0.21 est, Raises FY Guidance to \$590m to \$610M, Est \$538.8M

Financial news for HZNP dated on 2015-05-08: Horizon Pharma Announces Settlement of PENNSAID 2% Patent Litigation With Perrigo; Horizon Grants Perrigo Non-Exclusive Right to Market Generic Diclofenac Sodium Topical 2% W/W Solution in US

Financial news for HZNP dated on 2015-05-08: Earnings Scheduled For May 8, 2015

Financial news for HZNP dated on 2015-04-27: Option Alert: Horizon Pharma May \$35 Call; 1000 Contract Trade above Ask @\$0.47; Now \$30.10

Financial news for HZNP dated on 2015-04-27: Horizon Pharma Announces USPTO Issue of Added Notice of Allowance with Claims Covering PENNSAID(R) 2%

Financial news for HZNP dated on 2015-04-22: Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS Delayed-Release Tablets

Financial news for HZNP dated on 2015-04-20: Stifel Asks: How High Will Horizon Pharma Guidance Go?

Financial news for HZNP dated on 2015-04-17: Horizon Pharma Recieves US Patent, Trademark Office Issuance of Additional Notice of Allowance With Claims Covering PENNSAID 2%

Financial news for HZNP dated on 2015-04-15: Horizon Pharma Prices 15.4M Shares at \$28.25/Share

Financial news for HZNP dated on 2015-04-13: Horizon Pharma plc Announces Proposed Public Offering of 12M Ordinary Shares

Financial news for HZNP dated on 2015-04-10: Stocks Hitting 52-Week Highs

Financial news for HZNP dated on 2015-04-10: Morning Market Gainers

Financial news for HZNP dated on 2015-04-10: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2015-04-10: Horizon Pharma Given FDA Fast Track Designation for ACTIMMUNE in the Treatment of Friedreich's Ataxia

Financial news for HZNP dated on 2015-04-09: Extreme Networks, Citrix And AngioDynamics Lead Thursday's After-Hours Movers

Financial news for HZNP dated on 2015-03-31: Cantor Fitzgerald Downgrades Hyperion After Acquisition

Financial news for HZNP dated on 2015-03-31: Piper Jaffray Upgrades Horizon Pharma To Overweight

Financial news for HZNP dated on 2015-03-31: Benzinga's Top Upgrades

Financial news for HZNP dated on 2015-03-31: Horizon Pharma Shares Rise 3% Premarket Following Several Analyst PT Increases

Financial news for HZNP dated on 2015-03-31: Piper Jaffray Upgrades Horizon Pharma to Overweight, Raises PT to \$31.00

Financial news for HZNP dated on 2015-03-30: Benzinga's M&A Chatter for Monday March 30, 2015

Financial news for HZNP dated on 2015-03-30: Benzinga's Volume Movers

Financial news for HZNP dated on 2015-03-30: Stocks Hitting 52-Week Highs

Financial news for HZNP dated on 2015-03-30: Monday's Merger Mania

Financial news for HZNP dated on 2015-03-30: Morning Market Gainers

Financial news for HZNP dated on 2015-03-30: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2015-02-27: Morning Market Gainers

Financial news for HZNP dated on 2015-02-27: Friday's #PreMarket Movers: JC Penney Down Following Q4 Earnings

Financial news for HZNP dated on 2015-02-27: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2015-02-27: Horizon Pharma Q4 EPS \$0.27 vs \$0.22, Revenue \$103.8M vs \$95.5M

Financial news for HZNP dated on 2015-02-27: Earnings Scheduled For February 27, 2015

Financial news for HZNP dated on 2015-02-17: Horizon Pharma Opens Chicago Office

Financial news for HZNP dated on 2015-02-13: Horizon Pharma plc Submits NDA For ACTIMMUNE

Financial news for HZNP dated on 2015-02-11: JMP Securities Covers Mostly Good News From Pharma Pending More Visibility

Financial news for HZNP dated on 2015-02-04: POZEN Announces Issuance of VIMOVO Related Patent by USPTO

Financial news for HZNP dated on 2015-02-04: POZEN Announces Issuance of VIMOVO Related Patent

Financial news for HZNP dated on 2015-02-04: Horizon Pharma plc Announces Issuance of VIMOVO Related Patent

Financial news for HZNP dated on 2015-01-12: Horizon Pharma Offers Business Update: Reports Accelerated Expansion of PME(TM) Program, Launch of PENNSAID(R)2% in US; Secures Deal with FDA on ACTIMMUNE Phase 3 Trial Primary Endpoint

Financial news for HZNP dated on 2014-12-24: Horizon Pharma Reports Filing of Patent Infringement Suit Against Watson Labs for Filing ANDA Against PENNSAID(R) 2%

Financial news for HZNP dated on 2014-12-03: Horizon Pharma Exec Currently Speaking on Webcast for Piper Jaffray Conference: Affirms FY15 Sales Outlook

Financial news for HZNP dated on 2014-11-18: Horizon Pharma plc Announces Presentation Of Data Showing Unmet Need In Rheumatoid Arthritis And The Positive Effect of RAYOS

Financial news for HZNP dated on 2014-11-14: Horizon Pharma Announces Pricing Of 11.6M Secondary Offering At \$12.05/share

Financial news for HZNP dated on 2014-11-13: Horizon Pharma Announces 11.6M Proposed Secondary Offering of Ordinary Shares by Selling Shareholders

Financial news for HZNP dated on 2014-11-12: Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release Tablets Patent Infringement Litigation

Financial news for HZNP dated on 2014-11-06: Horizon Pharma Shares Rise 7.5% Premarket Following Strong Earnings Report

Financial news for HZNP dated on 2014-11-06: Horizon Pharma, Inc. Reports Q3 EPS of \$0.24 vs \$0.17 Est; Revenue of \$75.10M vs \$73.17M Est

Financial news for HZNP dated on 2014-10-23: POZEN Announces Receipt Of Three Patents From The United States Patent And Trademark Office

Financial news for HZNP dated on 2014-10-17: Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID

Financial news for HZNP dated on 2014-10-13: Horizon Pharma plc Hosting Conference Tonight to Discuss Opportunities For ACTIMMUNE

Financial news for HZNP dated on 2014-10-09: Horizon Pharma Presents Results of ACTIMMUNE(R) Phase 2 Data, Says Results Show Statistical Significant

Financial news for HZNP dated on 2014-10-03: Horizon Pharma plc Receives Orphan-Drug Designation for ACTIMMUNE

Financial news for HZNP dated on 2014-10-01: Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance

Financial news for HZNP dated on 2014-09-26: Horizon Pharma Reports Formation of Exec Committee; Todd Smith Resigns as Exec VP, Chief Commercial Officer

Financial news for HZNP dated on 2014-09-19: Shares of Horizon Pharma Resume Trade, Now Up ~6%

Financial news for HZNP dated on 2014-09-19: Horizon Pharma Reports Closing of Vidara Purchase; Reaffirms FY14, FY15 Outlook

Financial news for HZNP dated on 2014-09-09: Hearing Avondale Initiates Horizon Pharma with \$22 PT, Outperform Rating

Financial news for HZNP dated on 2014-08-27: Horizon Pharma Announces Notice Of Allowance For U.S. Patent

Financial news for HZNP dated on 2014-08-08: Horizon Pharma Offers Update on Effectiveness of S-4 Registration

Financial news for HZNP dated on 2014-08-07: Morning Market Movers

Financial news for HZNP dated on 2014-08-07: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2014-08-07: Horizon Pharma, Inc. Reports Q2 EPS of \$0.21 Which May Not Compare \$0.10 Est; Revenue of \$66.10M Which May Not Compare \$58.35M Est

Financial news for HZNP dated on 2014-08-05: Horizon Pharma Spikes Higher

Financial news for HZNP dated on 2014-08-05: Horizon Pharma Announces Two Notices of Allowance From USPTO

Financial news for HZNP dated on 2014-07-30: Horizon Pharma Shares Move Higher on Volume

Financial news for HZNP dated on 2014-07-29: Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties

Financial news for HZNP dated on 2014-07-29: Morning Market Losers

Financial news for HZNP dated on 2014-07-29: Piper Jaffray Downgrades Horizon Pharma, Inc. to Neutral, Lowers PT to \$9.00

Financial news for HZNP dated on 2014-07-28: Markets Little Changed Ahead Of The Federal Reserve's Policy Decision

Financial news for HZNP dated on 2014-07-28: Morning Market Losers

Financial news for HZNP dated on 2014-07-28: Benzinga's Top #PreMarket Losers

Financial news for HZNP dated on 2014-07-28: Horizon Pharma Announces CVS Caremark, Express Scripts Expect to Announce DUEXIS, VIMOVO Will No Longer be on Formularies; Will be Placed on Exclusion Lists Effective January 1, 2015

Financial news for HZNP dated on 2014-07-23: Horizon Pharma Shares Move Lower; May be Attributed to Seeking Alpha Post

Financial news for HZNP dated on 2014-06-18: Horizon Pharma Announces CFO Stepping Down, Replaced With Paul Hoelscher

Financial news for HZNP dated on 2014-05-30: Benzinga's Top Initiations

Financial news for HZNP dated on 2014-05-30: Guggenheim Securities Initiates Coverage on Horizon Pharma, Inc. at Buy, Announces \$31.00 PT

Financial news for HZNP dated on 2014-05-09: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2014-05-09: Horizon Pharma Sees FY2014 Sales \$270.0M-280.0M vs \$260.37M Est

Financial news for HZNP dated on 2014-05-09: Horizon Pharma Reports Q1 Adjusted EPS of \$0.13 vs \$0.01 Est

Financial news for HZNP dated on 2014-05-09: Earnings Scheduled For May 9, 2014

Financial news for HZNP dated on 2014-04-23: Horizon Pharma Reports Inducement Grants

Financial news for HZNP dated on 2014-04-16: Horizon Pharma Announces Early Termination of Hart-Scott-Rodino Waiting Period for Acquisition of Vidara Therapeutics International Ltd

Financial news for HZNP dated on 2014-04-11: Option Alert: Horizon Pharma May \$13 Call; 5,000 Contract Trade at Ask @\$1.55; Currently \$12.55; OI is 167

Financial news for HZNP dated on 2014-04-10: Horizon Pharma Reports US PTO Issued Added Notice of Allowance with Claims Covering RAYOS

Financial news for HZNP dated on 2014-04-03: Mid-Afternoon Market Update: Markets Go Red as Anadarko Rallies on Settlement with US

Financial news for HZNP dated on 2014-04-03: Mid-Day Market Update: US Stocks Fall; Google Shares Rise After Stock Split

Financial news for HZNP dated on 2014-03-28: Horizon Pharma Shares Not Affected Following 13D from Vidara Therapeutics Shows 17.6% Stake

Financial news for HZNP dated on 2014-03-19: Market Wrap For March 19: Yellen Hints of Higher Rates & Sooner Than Expected End To Taper

Financial news for HZNP dated on 2014-03-19: Benzinga's M&A Chatter for Wednesday March 19, 2014

Financial news for HZNP dated on 2014-03-19: Amended 13D Filing from Discovery Group on Horizon Pharma Shows 4.8% Stake

Financial news for HZNP dated on 2014-03-19: Mid-Afternoon Market Update: Markets Drop Sharply During Janet Yellen's First Conference

Financial news for HZNP dated on 2014-03-19: Afternoon Movers for Wednesday, March 19th 2014

Financial news for HZNP dated on 2014-03-19: Mid-Day Market Update: Oracle Shares Decline On Weak Results; Horizon Pharma Jumps

Financial news for HZNP dated on 2014-03-19: Top Trending Tickers On StockTwits For March 19

Financial news for HZNP dated on 2014-03-19: Mid-Morning Market Update: Markets Edge Higher; FedEx Profit Misses Estimates

Financial news for HZNP dated on 2014-03-19: Stocks Hitting 52-Week Highs

Financial news for HZNP dated on 2014-03-19: Morning Market Movers

Financial news for HZNP dated on 2014-03-19: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2014-03-19: Shares of Horizon Pharma Resume Trade Up 12.5%

Financial news for HZNP dated on 2014-03-19: Adam Feuerstein tweets: '\$HZNP is your latest spec pharma to ride the magical leprechaun rainbow to Ireland. Buying a tax haven (Vidara Therapeutics) for \$660M.'

Financial news for HZNP dated on 2014-03-19: UPDATE: Horizon Pharma Announces the Purchase of Vidara Therapeutics for \$660M in Stock, Cash

Financial news for HZNP dated on 2014-03-19: Shares of Horizon Pharma to Resume Trade at 7:30AM EDT

Financial news for HZNP dated on 2014-03-19: Horizon Pharma Shares Were Halted to Announce the Purchase of Vidara Therapeutics for \$660M in Stock, Cash

Financial news for HZNP dated on 2014-03-13: Morning Market Losers

Financial news for HZNP dated on 2014-03-13: Benzinga's Top #PreMarket Losers

Financial news for HZNP dated on 2014-03-13: Horizon Pharma Reports Q4 Adjusted EPS of \$(0.04) vs \$(0.08) Est; Revenue of \$30.10M vs \$32.18M Est

Financial news for HZNP dated on 2014-03-13: Earnings Scheduled For March 13, 2014

Financial news for HZNP dated on 2014-03-10: Perion Network, Horizon Pharma, Manitex, Attunity, Galena Biopharma, Concert Pharmaceuticals, Spansion, Magellan Petroleum, JAKKS Pacific Presenting at Roth Conference at 12:00 PM ET

Financial news for HZNP dated on 2014-03-06: Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Financial news for HZNP dated on 2014-03-05: UPDATE: Horizon Pharma Shares Turn Positive as Piper Jaffray Boosts Target from \$17 to \$21 in Mid-Day Research Note

Financial news for HZNP dated on 2014-03-05: Hearing Piper Raises PT on Horizon Pharma to \$21; Shares Spike Higher

Financial news for HZNP dated on 2014-03-05: Horizon Pharma Names Robert F. Carey Executive Vice President and Chief Business Officer

Financial news for HZNP dated on 2014-03-03: Amended 13D Filing from Discovery Group on Horizon Pharma Shows 6.3% Stake

Financial news for HZNP dated on 2014-02-18: Horizon Pharma IR Says Nothing Reported by Company Causing the Strength in Share Price; May be Attributed to Actavis Acquisition of Forest Labs

Financial news for HZNP dated on 2014-02-18: Horizon Pharma Spikes Higher

Financial news for HZNP dated on 2014-02-11: Horizon Pharma Issues Update on Feb. 10-11th FDA Joint Panel Meeting on CV Risk of NSAIDs

Financial news for HZNP dated on 2014-01-21: Option Alert: Horizon Pharma Jan 2015 \$10 Call; 5,000 Contract Trade Between Bid and Ask @\$1.80; Currently \$8.70

Financial news for HZNP dated on 2014-01-08: Horizon Pharma January 2015 Call; 4,050 Contract Trade Between Bid and Ask @\$1.75; Currently \$8.83

Financial news for HZNP dated on 2014-01-02: Horizon Pharma Reports Availability of Vimovo(R) in US

Financial news for HZNP dated on 2013-11-22: Horizon Pharma Announces Par Pharmaceutical to withdraw ANDA with FDA for a Generic Version of RAYOS Containing 2 mg and 5 mg of Prednisone -8K

Financial news for HZNP dated on 2013-11-21: Market Wrap For November 21: Dow Re-Claims 16,000 level On Positive Job Data

Financial news for HZNP dated on 2013-11-19: Stocks Hitting 52-Week Highs

Financial news for HZNP dated on 2013-11-19: Morning Market Movers

Financial news for HZNP dated on 2013-11-19: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2013-11-19: Horizon Pharma Announces Pricing of \$150M of 5.00% Convertible Senior Notes

Financial news for HZNP dated on 2013-11-19: Horizon to Acquire US Rights for VIMOVO from Pozen

Financial news for HZNP dated on 2013-11-11: Horizon Pharma, Mundipharma Report Exclusive Deal to Commercialize LODOTRA in Mid East, Africa

Financial news for HZNP dated on 2013-11-08: Benzinga's Top #PreMarket Gainers

Financial news for HZNP dated on 2013-11-08: Horizon Pharma Reports Q3 EPS of \$(0.03) Which May Not Compare \$(0.25) Est; Revenue of \$26.22M Which May Not Compare \$18.31M Est

Financial news for HZNP dated on 2013-10-23: Form 8-K from Horizon Pharma Shows Co. Jagotec Have Filed Suit on Generic Rayos vs Par Pharma

Financial news for HZNP dated on 2013-10-21: Benzinga's Top Pre-Market Gainers

Financial news for HZNP dated on 2013-10-21: Horizon Pharma Reports Clinical Data on RAYOS Tablets Which Will Be Presented at American College of Rheumatology Annual Meeting

Financial news for HZNP dated on 2013-10-21: Benzinga's Top Upgrades

Financial news for HZNP dated on 2013-10-21: Piper Jaffray Upgrades Horizon Pharma, Inc. to Overweight, Raises PT to \$7.00

Financial news for HZNP dated on 2013-09-05: Horizon Pharma Reports Sanofi Compiegne as Added Manufacturing Site for DUEXIS

Financial news for HZNP dated on 2013-08-27: Horizon Pharma Files Patent Infringement Suit vs. Watson Labs Related to ANDA

Financial news for HZNP dated on 2013-08-22: Horizon Pharma Reports Settlement of DUEXIS Patent Litigation with Par Pharma

Financial news for HZNP dated on 2013-08-09: Horizon Pharma, Inc. Reports Q2 EPS of \$(0.24) vs \$(0.32) Est; Revenue of \$17.60M vs \$16.09M Est

Financial news for HZNP dated on 2013-05-13: Benzinga Market Primer: Monday, May 13

Financial news for HZNP dated on 2013-05-10: Benzinga Market Primer: Friday, May 10

Financial news for HZNP dated on 2013-05-10: Horizon Pharma, Inc. Reports Q1 EPS of \$(0.03) vs \$(0.35) Est; Revenue of \$9.20M vs \$9.47M Est

Financial news for HZNP dated on 2013-03-25: Market Wrap for Monday, March 25: Stocks Fall Despite Cyprus Deal

Financial news for HZNP dated on 2013-03-19: UPDATE: Piper Jaffray Reiterates Horizon Pharma at Neutral Following Q4 Earnings

Financial news for HZNP dated on 2013-03-18: Horizon Pharma Tops EPS Estimates, Falls Short on Revenue

Financial news for HZNP dated on 2013-03-18: Horizon Pharma, Inc. Reports Q4 EPS of \$(0.40) vs \$(0.47) Est; Revenue of \$6.75M vs \$7.59M Est

Financial news for HZNP dated on 2013-03-18: Benzinga Market Primer, Monday March 18

Financial news for HZNP dated on 2013-03-18: Earnings Scheduled For March 18, 2013

Financial news for HZNP dated on 2013-03-07: Horizon Pharma Wins Marketing Authorization for DUEXIS from UK Medicines, Healthcare Products Regulatory Agency

Financial news for HZNP dated on 2013-02-11: Horizon Pharma Reports Prelim. Q4 Sales \$6.7M, Announces Changes to Recognizing Sales on Some Prescriptions

Financial news for HZNP dated on 2012-12-21: Benzinga's Top Pre-Market Gainers

Financial news for HZNP dated on 2012-12-03: Horizon Pharma Commences Initial Commercial Launch of RAYOS(R)

Financial news for HZNP dated on 2012-11-13: Earnings Scheduled For November 13, 2012

Financial news for HZNP dated on 2012-11-08: Horizon Pharma Spikes Lower

Financial news for HZNP dated on 2012-10-16: Stifel Nicolaus Maintains Horizon Pharma at Buy, Lowers PT from \$9 to \$6

Financial news for HZNP dated on 2012-10-15: From Earlier: Horizon Pharma Announces US Patent for Rayos Tablet

Financial news for HZNP dated on 2012-09-28: Horizon Pharma Announces Receipt of Two Additional U.S. Patent Allowances for DUEXIS

Financial news for HZNP dated on 2012-09-20: Morning Market Losers

Financial news for HZNP dated on 2012-09-20: Horizon Pharma Prices \$75 Million Public Offering of Common Stock and Warrants to Purchase Common Stock

Financial news for HZNP dated on 2012-09-20: Horizon Pharma Prices \$75M Offering of Stock-Warrants

Financial news for HZNP dated on 2012-09-20: Horizon Pharma Falls 10% Pre-Market on Stock, Warrant Offering

Financial news for HZNP dated on 2012-09-19: Horizon Pharma Announces Proposed Public Offering of Common Stock

Financial news for HZNP dated on 2012-08-14: Horizon Pharma Enters into Sales Agreement with Cowen and Company

Financial news for HZNP dated on 2012-08-13: Discovery Group Discloses 7.5% Stake in Horizon Pharma

Financial news for HZNP dated on 2012-08-13: UPDATE: Discovery Group May Seek Talks with Horizon Management

Financial news for HZNP dated on 2012-08-13: Discovery Group Has 7.5% Stake in Horizon Pharma

Financial news for HZNP dated on 2012-08-10: Horizon Pharma Reports Q2 EPS \$-0.62 vs \$-0.66 Est; Revenues \$3.8M vs \$4.44M Est

Financial news for HZNP dated on 2012-08-10: Horizon Pharma Reports Q2 EPS \$-0.68 vs \$-0.66 Est; Revenues \$3.8M vs \$4.44M Est

Financial news for HZNP dated on 2012-08-10: Horizon Pharma Announces Second Quarter 2012 Financial Results and Provides Business Update

Financial news for HZNP dated on 2012-08-10: Earnings Scheduled For August 10, 2012

Financial news for HZNP dated on 2012-08-01: Horizon Pharma Files Mixed-Securities Shelf for up to \$175 Million

Financial news for HZNP dated on 2012-07-27: Option Alert: Horizon Pharma Call Volume at 2,000% of Average; Currently \$6.27

Financial news for HZNP dated on 2012-07-26: Horizon Pharma Updates Filing

Financial news for HZNP dated on 2012-07-26: Horizon Pharma Resumes Trading

Financial news for HZNP dated on 2012-07-26: PREVIEW: Horizon Pharma to Resume at 4:40pm

Financial news for HZNP dated on 2012-07-26: Horizon's Rayos Gets FDA Approval

Financial news for HZNP dated on 2012-07-26: Horizon Pharma Announces FDA Approval of RAYOS Delayed-Release Tablets for Rheumatoid Arthritis and Multiple Additional Indications

Financial news for HZNP dated on 2012-07-26: Horizon Pharma Halted Pending News

Financial news for HZNP dated on 2012-07-26: Horizon Pharma Falls 5% Pre-Market on Martin Shkreli Tweet

Financial news for HZNP dated on 2012-07-25: Horizon's Rayos FDA Approval Thursday Seems Likely -Adam F Tweet

Financial news for HZNP dated on 2012-07-24: Horizon Pharma Spiking Higher

Financial news for HZNP dated on 2012-07-23: Amarin and Horizon Pharma Higher Ahead of PDUFA Dates

Financial news for HZNP dated on 2012-07-18: Biotechs With Upcoming PDUFA Dates

Financial news for HZNP dated on 2012-07-10: Option Alert: Horizon Pharma Call Volume at 1001% of Average; Currently \$7.22

Financial news for HZNP dated on 2012-06-25: Spokesperson for Horizon Pharma Cites Recent Marketing Agreement Announcements for DUEXIS for the US and Latin America as Cause of Recent Strenth

Financial news for HZNP dated on 2012-06-19: The Grunenthal Group Enters into Exclusive Agreement with Horizon Pharma for Commercialization of DUEXIS(r) in Latin America

Financial news for HZNP dated on 2012-06-19: Horizon Pharma Enters into Exclusive Agreement with Grunenthal for Commercialization of DUEXIS(r) in Latin America

Financial news for HZNP dated on 2012-06-18: Mallinckrodt Announces Co-Promotion Arrangement for DUEXIS(r)

Financial news for HZNP dated on 2012-05-29: Horizon Pharma Announces Issuance of U.S. Patent Covering RAYOS (delayed-release prednisone)

Financial news for HZNP dated on 2012-05-07: Horizon Pharma Announces Annals of the Rheumatic Diseases Publishes Pivotal Phase 3 Study Demonstrating Efficacy and Safety of RAYOS in Combination With DMARD Therapy in Rheumatoid Arthritis Patients

Financial news for HZNP dated on 2012-03-28: Horizon Pharma Files Patent Infringement Suit Against Par

Financial news for HZNP dated on 2012-03-07: Horizon Pharma Enters Into Exclusive Agreement With Mundipharma

Financial news for HZNP dated on 2012-02-29: Horizon Pharma Announces \$50.8M Private Placement

Financial news for HZNP dated on 2012-02-29: Horizon Pharma Halted, Pending News

Financial news for HZNP dated on 2012-02-22: Horizon Pharma Secures \$60 Million Loan Facility

Financial news for HZNP dated on 2012-02-17: From Earlier: Horizon Receives Notice of Paragraph IV Certification Against Patents for DUEXIS

Financial news for HZNP dated on 2012-02-13: Horizon Pharma Modifies DUEXIS Marketing Authorization Application to Include Recently Approved Manufacturing Site

Financial news for HZNP dated on 2011-12-05: Horizon Pharma Announces Launch of DUEXIS 800 mg/26.6 mg in the United States

Financial news for HZNP dated on 2011-12-05: Horizon Pharma Announces Launch of DUEXIS 800 mg/26.6 mg in the United States

Financial news for HZNP dated on 2011-11-29: Financial Breakfast: Morning News Summary for November 29, 2011

Financial news for HZNP dated on 2011-11-29: Horizon Pharma Announces U.S. Food and Drug Administration Acceptance of LODOTR

Financial news for HZNP dated on 2011-11-29: Horizon Pharma Announces U.S. Food and Drug Administration Acceptance of LODOTRA New Drug Application

Financial news for HZNP dated on 2011-11-14: Horizon Pharma and Sanofi Announce FDA Approval of DUEXIS(R) Commercial Manufacturing Facility

Financial news for HZNP dated on 2011-10-13: Horizon Pharma Receives U.S. Patent Allowance for DUEXIS(R) in the United States

Financial news for HZNP dated on 2011-09-30: Horizon Pharma Adds Two New Biopharmaceutical Executives to Its Board of Directors

Financial news for HZNP dated on 2011-09-28: Horizon Pharma Submits New Drug Application for LODOTRA for the Treatment of Rheumatoid Arthritis

Financial news for HZNP dated on 2011-09-28: Horizon Pharma Submits New Drug Application for LODOTRA(R) for the Treatment of Rheumatoid Arthritis

Financial news for HZNP dated on 2011-09-07: UPDATE: Stifel Nicolaus Initiates Horizon Pharma at Buy

Financial news for HZNP dated on 2011-09-07: Stifel Nicolaus Initiates Horizon Pharma At Buy, \$12 PT

Financial news for HZNP dated on 2011-09-06: Horizon Pharma Receives U.S. Patent Allowance for DUEXIS

Financial news for HZNP dated on 2011-08-31: Horizon Pharma Reports Q2 EPS (\$5.54), Revenue \$1.3M

Financial news for HZNP dated on 2011-07-28: IPO Horizon Pharma Inc Opens at \$9 After Original Pricing at \$9/Share

Financial news for HZNP dated on 2011-07-28: Horizon Pharma Announces Pricing of Its IPO at \$9.00 per Share